Antibodies against LIF and dosage forms thereof
Anti-LIF antibodies effectively target and reduce tumor volume in cancer models by blocking LIF activity, addressing the poor prognosis associated with high LIF levels in cancers.
Patent Information
- Application Number
- JP2024130558
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-05-03
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
High expression levels and serum levels of leukemia inhibitory factor (LIF) are associated with poor prognosis in various cancers, and existing treatments lack effective methods to antagonize or block LIF activity.
Development of anti-LIF antibodies that specifically bind to LIF, administered in therapeutically effective doses to reduce tumor volume in cancer models, including murine and non-human primate models.
The anti-LIF antibodies demonstrate significant efficacy in reducing tumor volume and modulating immune responses, indicating potential therapeutic benefits for cancer treatment.
Smart Images

Figure 2024160301000032 
Figure 2024160301000033 
Figure 2024160301000034
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of European Patent Application Publication No. 18382327.7, filed May 14, 2018, European Patent Application Publication No. 18382359.0, filed May 25, 2018, European Patent Application Publication No. 19382208.7, filed March 26, 2019, and European Patent Application Publication No. 19382331.7, filed May 3, 2019, each of which is incorporated herein in its entirety. [Background technology]
[0002] Leukemia inhibitory factor (LIF) is an interleukin 6 (IL-6) type cytokine that is involved in a variety of biological activities, including the inhibition of cell differentiation. Human LIF is a 202 amino acid polypeptide that exerts its biological effects by binding to the cell surface LIF receptor (LIFR or CD118) that heterodimerizes with gp130. This leads to the activation of growth-promoting signaling pathways, such as the mitogen-activated protein kinase (MAPK) and Janus-activated kinase (JAK / STAT) pathways. High expression levels and high serum levels of LIF have been shown to be associated with poor prognosis for many types of cancer. Summary of the Invention [Means for solving the problem]
[0003] Described herein are anti-LIF antibodies that antagonize or block LIF activity. The anti-LIF antibodies described herein are useful for treating cancer. In particular, certain anti-LIF antibodies, when administered in therapeutically effective amounts, have produced excellent and surprising efficacy in reducing tumor volume in both mouse and non-human primate cancer models. Thus, the present disclosure includes methods and pharmaceutical compositions for treating cancer using specific anti-LIF antibodies at specific doses (both weight-based and flat doses).
[0004] In one aspect, described herein is a method of treating an individual having cancer, comprising administering to the individual: (a) an immunoglobulin heavy chain complementarity determining region 1 (VH-CDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1-3; (b) an immunoglobulin heavy chain complementarity determining region 2 (VH-CDR2) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 4 or 5; (c) an immunoglobulin heavy chain complementarity determining region 3 (VH-CDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6-8; (d) an immunoglobulin heavy chain complementarity determining region 4 (VH-CDR4) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 9 or 10. (e) an immunoglobulin light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 11 or 12; and (5) an immunoglobulin light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence set forth in SEQ ID NO: 13, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg (milligrams). In some embodiments, the recombinant antibody binds to glycosylated LIF. In some embodiments, the recombinant antibody comprises at least one framework region derived from a human antibody framework region. In some embodiments, the recombinant antibody is humanized. In some embodiments, the recombinant antibody is deimmunized. In some embodiments, the recombinant antibody comprises two immunoglobulin heavy chains and two immunoglobulin light chains. In certain embodiments, the recombinant antibody is an IgG antibody. In certain embodiments, the recombinant antibody is an Fab, F(ab) 2 , single domain antibody, single chain variable fragment (scFv) or nanobody. In certain embodiments, the recombinant antibody has a dissociation constant (K D In certain embodiments, the recombinant antibody specifically binds to LIF with a dissociation constant (K) of less than about 100 picomolar. DIn certain embodiments, VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:1 (GFTFSHAWMH), VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:4 (QIKAKSDDYATYYAESVKG), VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:6 (TCWEWDLDF), VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:9 (RSSQSLLDSDGHTYLN), VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:11 (SVSNLES), and VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:13 (MQATHAPPYT). In certain embodiments, VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:2 (GFTFSHAW), VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:5 (IKAKSDDYAT), VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:6 (TCWEWDLDF), VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:10 (QSLLDSDGHTYLN), VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:12 (SVS), and VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:13 (MQATHAPPYT). In certain embodiments, VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:3 (HAWMH), VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:4 (QIKAKSDDYATYYAESVKG), VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:7 (WEWDLDF), VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:9 (RSSQSLLDSDGHTYLN), VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:11 (SVSNLES), and VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:13 (MQATHAPPYT).In certain embodiments, the recombinant antibody comprises one or more heavy chain framework 1 (VH-FR1) region amino acid sequences that are at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 14-17, a heavy chain framework 2 (VH-FR2) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 18 or 19, a heavy chain framework 3 (VH-FR3) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 20-22, and a heavy chain framework 4 (VH-FR4) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 23-25. In certain embodiments, the recombinant antibody comprises one or more heavy chain framework 1 (VH-FR1) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 14-17, heavy chain framework 2 (VH-FR2) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 18 or 19, heavy chain framework 3 (VH-FR3) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 20-22, and heavy chain framework 4 (VH-FR4) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 23-25.In certain embodiments, the recombinant antibody comprises one or more light chain framework 1 (VL-FR1) region amino acid sequences that are at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 26-29, a light chain framework 2 (VL-FR2) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 30-33, a light chain framework 3 (VL-FR3) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 34-37, and a light chain framework 4 (VL-FR4) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 38-40. In certain embodiments, the recombinant antibody comprises one or more light chain framework 1 (VL-FR1) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 26-29, one or more light chain framework 2 (VL-FR2) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 30-33, one or more light chain framework 3 (VL-FR3) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 34-37, and one or more light chain framework 4 (VL-FR4) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 38-40. In certain embodiments, the recombinant antibody binds to at least one of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In certain embodiments, the recombinant antibody binds to at least five of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68.In some embodiments, the recombinant antibody binds to at least ten of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In some embodiments, the recombinant antibody binds to all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In some embodiments, the cancer comprises an advanced solid tumor, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, kidney cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma, or soft tissue cancer. In some embodiments, the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma. In some embodiments, the recombinant antibody is administered as a component of a pharmaceutical formulation, the pharmaceutical formulation comprising the recombinant antibody and further comprising a pharma- ceutically acceptable excipient, carrier, or diluent. In some embodiments, the pharmaceutical formulation has a pH of about 6.0. In some embodiments, the pharmaceutical formulation comprises about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80, where the recombinant antibody is present at a concentration of about 20 mg / mL. In some embodiments, the recombinant antibody is administered intravenously. In some embodiments, the recombinant antibody is administered once a week. In some embodiments, the recombinant antibody is administered about once every other week. In some embodiments, the recombinant antibody is administered about once every three weeks. In some embodiments, the recombinant antibody is administered about once every four weeks. In some embodiments, the recombinant antibody is administered at a dose of about 75 mg. In some embodiments, the recombinant antibody is administered at a dose of about 225 mg. In some embodiments, the recombinant antibody is administered at a dose of about 750 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1125 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1500 mg. In some embodiments, the recombinant antibody is administered at a dose of about 2000 mg.
[0005] In another aspect, described herein is a method of treating an individual having cancer, the method comprising administering to the individual: (a) an immunoglobulin heavy chain variable region (VH) sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 41, 42, 44 or 66, and (b) an immunoglobulin light chain variable region (VL) sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 45-48, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg. In some embodiments, the VH sequence is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 42; and the VL sequence is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 46. In some embodiments, the VH sequence is identical to the amino acid sequence set forth in SEQ ID NO: 42; and the VL sequence is identical to the amino acid sequence set forth in SEQ ID NO: 46. In some embodiments, the recombinant antibody comprises two heavy immunoglobulin chains and two light immunoglobulin chains. In some embodiments, the recombinant antibody is an IgG antibody. In some embodiments, the cancer comprises an advanced solid tumor, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, kidney cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma or soft tissue cancer. In some embodiments, the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma. In some embodiments, the recombinant antibody is administered as a component of a pharmaceutical formulation, which comprises the recombinant antibody and further comprises a pharma- ceutically acceptable excipient, carrier, or diluent. In some embodiments, the pharmaceutical formulation has a pH of about 6.0. In some embodiments, the pharmaceutical formulation comprises about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80, wherein the recombinant antibody is present at a concentration of about 20 mg / mL. In some embodiments, the recombinant antibody is administered intravenously.In some embodiments, the recombinant antibody is administered about once per week. In some embodiments, the recombinant antibody is administered about once every other week. In some embodiments, the recombinant antibody is administered about once every three weeks. In some embodiments, the recombinant antibody is administered about once every four weeks. In some embodiments, the recombinant antibody is administered at a dose of about 75 mg. In some embodiments, the recombinant antibody is administered at a dose of about 225 mg. In some embodiments, the recombinant antibody is administered at a dose of about 750 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1125 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1500 mg. In some embodiments, the recombinant antibody is administered at a dose of about 2000 mg.
[0006] In another aspect, described herein is a method of treating an individual having cancer, the method comprising administering to the individual: (a) an immunoglobulin heavy chain sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 57-60 or 67, and (b) an immunoglobulin light chain sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 61-64, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg. In some embodiments, the immunoglobulin heavy chain sequence is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:58; and the immunoglobulin light chain sequence is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:62. In some embodiments, the immunoglobulin heavy chain sequence is identical to the amino acid sequence set forth in SEQ ID NO:58; and the immunoglobulin light chain sequence is identical to the amino acid sequence set forth in SEQ ID NO:62. In some embodiments, the recombinant antibody comprises two immunoglobulin heavy chains and two immunoglobulin light chains. In some embodiments, the recombinant antibody is an IgG antibody. In some embodiments, the cancer comprises an advanced solid tumor, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, kidney cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma or soft tissue cancer. In some embodiments, the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma. In some embodiments, the recombinant antibody is administered as a component of a pharmaceutical formulation, which comprises the recombinant antibody and further comprises a pharma- ceutically acceptable excipient, carrier, or diluent. In some embodiments, the pharmaceutical formulation has a pH of about 6.0. In some embodiments, the pharmaceutical formulation comprises about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80, wherein the recombinant antibody is present at a concentration of about 20 mg / mL. In some embodiments, the recombinant antibody is administered intravenously. In some embodiments, the recombinant antibody is administered about once a week.In some embodiments, the recombinant antibody is administered about once every two weeks. In some embodiments, the recombinant antibody is administered about once every three weeks. In some embodiments, the recombinant antibody is administered about once every four weeks. In some embodiments, the recombinant antibody is administered at a dose of about 75 mg. In some embodiments, the recombinant antibody is administered at a dose of about 225 mg. In some embodiments, the recombinant antibody is administered at a dose of about 750 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1125 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1500 mg. In some embodiments, the recombinant antibody is administered at a dose of about 2000 mg.
[0007] In another aspect, described herein is a pharmaceutical formulation for use in treating cancer in an individual, the pharmaceutical formulation comprising a pharma- ceutical acceptable excipient, carrier, or diluent and a recombinant antibody, the recombinant antibody specifically binds to leukemia inhibitory factor (LIF), and comprises: (a) an immunoglobulin heavy chain complementarity determining region 1 (VH-CDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1-3; (b) an immunoglobulin heavy chain complementarity determining region 2 (VH-CDR2) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 4 or 5; (c) an immunoglobulin heavy chain complementarity determining region 3 (VH-CDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6-8. (d) immunoglobulin heavy chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 9 or 10; (e) immunoglobulin light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 11 or 12; and (f) immunoglobulin light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence set forth in SEQ ID NO: 13, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg. In certain embodiments, the pharmaceutical formulation comprises about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80, wherein the recombinant antibody is present at a concentration of about 20 mg / mL. In certain embodiments, the pharmaceutical formulation has a pH of about 6.0. In some embodiments, the recombinant antibody binds to glycosylated LIF. In some embodiments, the recombinant antibody comprises at least one framework region derived from a human antibody framework region. In some embodiments, the recombinant antibody is humanized. In some embodiments, the recombinant antibody is deimmunized. In some embodiments, the recombinant antibody comprises two heavy immunoglobulin chains and two light immunoglobulin chains. In some embodiments, the recombinant antibody is an IgG antibody. In some embodiments, the recombinant antibody is a Fab, F(ab) 2 , single domain antibody, single chain variable fragment (scFv) or nanobody. In certain embodiments, the recombinant antibody has a dissociation constant (K DIn certain embodiments, the recombinant antibody specifically binds to LIF with a dissociation constant (K) of less than about 100 picomolar. DIn certain embodiments, VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:1 (GFTFSHAWMH), VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:4 (QIKAKSDDYATYYAESVKG), VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:6 (TCWEWDLDF), VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:9 (RSSQSLLDSDGHTYLN), VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:11 (SVSNLES), and VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:13 (MQATHAPPYT). In certain embodiments, VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:2 (GFTFSHAW), VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:5 (IKAKSDDYAT), VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:6 (TCWEWDLDF), VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:10 (QSLLDSDGHTYLN), VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:12 (SVS), and VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:13 (MQATHAPPYT). In certain embodiments, VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:3 (HAWMH), VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:4 (QIKAKSDDYATYYAESVKG), VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:7 (WEWDLDF), VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:9 (RSSQSLLDSDGHTYLN), VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:11 (SVSNLES), and VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:13 (MQATHAPPYT).In certain embodiments, the recombinant antibody comprises one or more heavy chain framework 1 (VH-FR1) region amino acid sequences that are at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 14-17, a heavy chain framework 2 (VH-FR2) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 18 or 19, a heavy chain framework 3 (VH-FR3) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 20-22, and a heavy chain framework 4 (VH-FR4) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 23-25. In certain embodiments, the recombinant antibody comprises one or more heavy chain framework 1 (VH-FR1) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 14-17, heavy chain framework 2 (VH-FR2) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 18 or 19, heavy chain framework 3 (VH-FR3) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 20-22, and heavy chain framework 4 (VH-FR4) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 23-25.In certain embodiments, the recombinant antibody comprises one or more light chain framework 1 (VL-FR1) region amino acid sequences that are at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 26-29, a light chain framework 2 (VL-FR2) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 30-33, a light chain framework 3 (VL-FR3) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 34-37, and a light chain framework 4 (VL-FR4) region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 38-40. In certain embodiments, the recombinant antibody comprises one or more light chain framework 1 (VL-FR1) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 26-29, one or more light chain framework 2 (VL-FR2) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 30-33, one or more light chain framework 3 (VL-FR3) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 34-37, and one or more light chain framework 4 (VL-FR4) region amino acid sequences identical to the amino acid sequences set forth in any one of SEQ ID NOs: 38-40. In certain embodiments, the recombinant antibody binds to at least one of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In certain embodiments, the recombinant antibody binds to at least five of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68.In some embodiments, the recombinant antibody binds to at least ten of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In some embodiments, the recombinant antibody binds to all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In some embodiments, the cancer comprises an advanced solid tumor, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, kidney cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma, or soft tissue cancer. In some embodiments, the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma. In some embodiments, the recombinant antibody is administered intravenously. In some embodiments, the recombinant antibody is administered about once per week. In some embodiments, the recombinant antibody is administered about once every other week. In some embodiments, the recombinant antibody is administered about once every three weeks. In some embodiments, the recombinant antibody is administered about once every four weeks. In some embodiments, the recombinant antibody is administered at a dose of about 75 mg. In some embodiments, the recombinant antibody is administered at a dose of about 225 mg. In some embodiments, the recombinant antibody is administered at a dose of about 750 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1125 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1500 mg. In some embodiments, the recombinant antibody is administered at a dose of about 2000 mg.
[0008] In another aspect, described herein is a pharmaceutical formulation for use in treating cancer in an individual, the pharmaceutical formulation comprising a pharma- ceutical acceptable excipient, carrier, or diluent and a recombinant antibody, the recombinant antibody specifically binds leukemia inhibitory factor (LIF), and comprising: (a) an immunoglobulin heavy chain variable region (VH) sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 41, 42, 44, or 66, and (b) an immunoglobulin light chain variable region (VL) sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 45-48, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg. In some embodiments, the pharmaceutical formulation comprises about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80, wherein the recombinant antibody is present at a concentration of about 20 mg / mL. In some embodiments, the pharmaceutical formulation has a pH of about 6.0. In some embodiments, the recombinant antibody binds to glycosylated LIF. In some embodiments, the VH sequence is at least about 80%, 90%, 95%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:42; and the VL sequence is at least about 80%, 90%, 95%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:46. In some embodiments, the VH sequence is identical to the amino acid sequence set forth in SEQ ID NO:42; and the VL sequence is identical to the amino acid sequence set forth in SEQ ID NO:46. In some embodiments, the recombinant antibody comprises two immunoglobulin heavy chains and two immunoglobulin light chains. In certain embodiments, the recombinant antibody is an IgG antibody. In certain embodiments, the recombinant antibody is an Fab, F(ab) 2 , single domain antibody, single chain variable fragment (scFv) or nanobody. In certain embodiments, the recombinant antibody has a dissociation constant (K D In certain embodiments, the recombinant antibody specifically binds to LIF with a dissociation constant (K) of less than about 100 picomolar. D) specifically binds to LIF. In some embodiments, the cancer comprises an advanced solid tumor, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, kidney cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma, or soft tissue cancer. In some embodiments, the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma. In some embodiments, the recombinant antibody is administered intravenously. In some embodiments, the recombinant antibody is administered about once per week. In some embodiments, the recombinant antibody is administered about once every other week. In some embodiments, the recombinant antibody is administered about once every three weeks. In some embodiments, the recombinant antibody is administered about once every four weeks. In some embodiments, the recombinant antibody is administered at a dose of about 75 mg. In some embodiments, the recombinant antibody is administered at a dose of about 225 mg. In some embodiments, the recombinant antibody is administered at a dose of about 750 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1125 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1500 mg. In some embodiments, the recombinant antibody is administered at a dose of about 2000 mg.
[0009] In another aspect, described herein is a pharmaceutical formulation for use in treating cancer in an individual, the pharmaceutical formulation comprising a pharma- ceutical acceptable excipient, carrier, or diluent, and a recombinant antibody, the recombinant antibody specifically binds to leukemia inhibitory factor (LIF), and comprising: (a) an immunoglobulin heavy chain sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98%, or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 57-60 or 67, and (b) an immunoglobulin light chain sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98%, or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 61-64, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg. In certain embodiments, the pharmaceutical formulation comprises about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80, wherein the recombinant antibody is present at a concentration of about 20 mg / mL. In certain embodiments, the pharmaceutical formulation has a pH of about 6.0. In certain embodiments, the recombinant antibody binds to glycosylated LIF. In certain embodiments, the immunoglobulin heavy chain sequence is at least about 80%, 90%, 95%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:58; and the immunoglobulin light chain sequence is at least about 80%, 90%, 95%, 97%, 98%, or 99% identical to the amino acid sequence set forth in SEQ ID NO:62. In certain embodiments, the immunoglobulin heavy chain sequence is identical to the amino acid sequence set forth in SEQ ID NO:58; and the immunoglobulin light chain sequence is identical to the amino acid sequence set forth in SEQ ID NO:62. In certain embodiments, the recombinant antibody comprises two heavy immunoglobulin chains and two light immunoglobulin chains. In certain embodiments, the recombinant antibody has a dissociation constant (K D In certain embodiments, the recombinant antibody specifically binds to LIF with a dissociation constant (K) of less than about 100 picomolar. D) specifically binds to LIF. In some embodiments, the cancer comprises an advanced solid tumor, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, kidney cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma, or soft tissue cancer. In some embodiments, the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma. In some embodiments, the recombinant antibody is administered intravenously. In some embodiments, the recombinant antibody is administered about once per week. In some embodiments, the recombinant antibody is administered about once every other week. In some embodiments, the recombinant antibody is administered about once every three weeks. In some embodiments, the recombinant antibody is administered about once every four weeks. In some embodiments, the recombinant antibody is administered at a dose of about 75 mg. In some embodiments, the recombinant antibody is administered at a dose of about 225 mg. In some embodiments, the recombinant antibody is administered at a dose of about 750 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1125 mg. In some embodiments, the recombinant antibody is administered at a dose of about 1500 mg. In some embodiments, the recombinant antibody is administered at a dose of about 2000 mg. [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 shows a Western blot showing inhibition of LIF-induced STAT3 phosphorylation by various anti-LIF humanized antibodies. [Diagram 2] [FIGS. 2A-2B] Western blots showing inhibition of LIF-induced STAT3 phosphorylation humanized and parental 5D8 antibodies. [Diagram 3] [Figure 3A] IC50 for LIF inhibition in U-251 cells using h5D8 antibody. [Figure 3B] Representative IC50 dose-response curves for r5D8 and h5D8 inhibition of pSTAT3 under endogenous LIF stimulation conditions. Representative curves are shown (n=1 h5D8, n=2 r5D8). [Figure 4] FIG. 1 shows a Western blot demonstrating inhibition of LIF-induced STAT3 phosphorylation by various monoclonal antibodies described in this disclosure. [Diagram 5] Immunohistological staining and quantification of LIF expression in glioblastoma multiforme (GBM), NSCLC (non-small cell lung cancer), ovarian cancer and colorectal cancer tumors from human patients. Bars represent the mean±SEM. [Figure 6] 1 is a graph showing an experiment performed in a mouse model of non-small cell lung cancer using humanized 5D8 antibody. [Figure 7] [Figure 7A] Effect of r5D8 on inhibition of U251 in an orthotopic mouse model of GBM. Quantitation at day 26 is shown. [Figure 7B] Data from mice inoculated with luciferase expressing human U251 GBM cells and then treated twice weekly with 100, 200 or 300 μg h5D8 or vehicle. Tumor size was determined by bioluminescence (Xenogen IVIS Spectrum) at day 7. Graphs show individual tumor measurements, with horizontal bars indicating mean ± SEM. Statistical significance was calculated using the unpaired nonparametric Mann-Whitney U test. [Figure 8] [Figure 8A] Effect of r5D8 on inhibition of ovarian cancer cell growth in a syngeneic mouse model. [Figure 8B] Individual tumor measurements on day 25. [Figure 8C] Significant reduction in tumor growth when h5D8 was administered to mice at a dose of 200 μg twice weekly (p<0.05). Symbols are mean + SEM, statistical significance compared to vehicle (using unpaired non-parametric Mann-Whitney U test). [Figure 9] [Figure 9A] Effect of r5D8 on inhibiting colorectal cancer growth in a syngeneic mouse model. [Figure 9B] Individual tumor measurements at day 17. [Figure 10][Fig. 10A] A diagram showing the reduction of macrophage infiltration at the tumor site in an orthotopic mouse model of GBM, with representative images and quantification of CCL22+ cells. [Fig. 10B] A diagram showing the reduction of macrophage infiltration in a human organotypic tissue slice culture model. Representative images (left) and quantification (right) are shown. [Fig. 10C] A diagram showing the reduction of macrophage infiltration at the tumor site in an orthotopic mouse model of ovarian cancer, with representative images and quantification of CCL22+ cells. [Fig. 10D] A diagram showing the reduction of macrophage infiltration at the tumor site in an orthotopic mouse model of colorectal cancer, with representative images and quantification of CCL22+ cells. [Figure 11] [Figure 11A] A diagram showing the increase in nonmyelin effector cells after treatment with r5D8 in an orthotopic mouse model of ovarian cancer. [Figure 11B] A diagram showing the increase in nonmyelin effector cells after treatment with r5D8 in an orthotopic mouse model of colon cancer. [Figure 11C] A diagram showing the decrease in the percentage of CD4+TREG cells after treatment with r5D8 in a mouse model of NSCLC cancer. [Figure 12] Figure 1 shows data from CT26 tumor-bearing mice treated twice weekly with PBS (control) or r5D8 administered intraperitoneally in the presence or absence of anti-CD4 and anti-CD8 depleting antibodies. Graph shows individual tumor measurements at day 13 presented as mean tumor volume + SEM. Statistical significance between groups was determined by unpaired non-parametric Mann-Whitney U test. R5D8 inhibited CT26 tumor growth (*p<0.05). Tumor growth inhibition by r5D8 was significantly reduced in the presence of anti-CD4 and anti-CD8 depleting antibodies (****p<0.0001). [Figure 13] [Figure 13A] Overview of the co-crystal structure of h5D8 Fab in complex with LIF. The gp130 interaction site is mapped on the surface of LIF (highly shaded). [Figure 13B] Detailed interactions of LIF and h5D8 showing residues forming salt bridges and h5D8 residues with a buried surface area of more than 100 Å2. [Figure 14][Figure 14A] Illustrates the superposition of five h5D8 Fab crystal structures, showing a high degree of similarity despite being crystallized in various chemical conditions. [Figure 14B] Illustrates the extensive network of van der Waals interactions mediated by unpaired Cys100. This residue is aligned and participates in shaping the conformation of HCDR1 and HCDR3, but does not participate in undesirable disulfide scrambling. The spacing between residues is labeled with dashed lines. [Figure 15] [Figure 15A] Figure illustrating the binding of h5D8 C100 mutants to human LIF by ELISA [Figure 15B] Figure illustrating the binding of h5D8 C100 mutants to mouse LIF by ELISA. [Figure 16] [Figure 16A] Figure illustrating that h5D8 does not block binding of LIF to LIFR by Octet. Sequential binding of h5D8 to LIF was followed by LIFR. [Figures 16B-16C] Figure illustrating ELISA analysis of LIF / mAb complex binding to immobilized LIFR or gp130. Species-specific peroxidase signals were bound to anti-IgG antibodies (anti-human for (-) and h5D8, anti-rat for r5d8 and B09) to detect antibody moieties of mAb / LIF complexes bound to immobilized LIFR (Figure 16B) or gp130 (Figure 16C) coated plates. [Figure 17] [Figures 17A-17B] Illustrates mRNA expression of LIF (Figure 16A) or LIFR (Figure 16B) in 72 human tissues. [Figure 18][FIGS. 18A-18C] Cycle 7 ("C7") of h5D8 (750 mg) treatment of three target lesions, two rectus muscle lesions, and one posterior pelvic vaginal vault lesion, as well as images of previous radiation therapy ports. FIG. 18A shows rectus muscle #1. Target lesion (1) is shown in the left panel, and XRT-irradiated lesion (2) is shown in the right panel. Size: 37.8 mm. FIG. 18B shows rectus muscle #2. Target lesion (3) is shown in the left panel, and XRT-irradiated lesion (4) is shown in the right panel. Size: 24.3 mm. FIG. 18C shows posterior pelvic vaginal vault. Target lesion (5) is shown in the right panel, and XRT-irradiated lesion (6) is shown in the right panel. Size: 25 mm. [Figure 19] FIG. 13 shows saturation LIF stabilization compared to duration of first dose for subject 0210-003. [Figure 20] [Figures 20A-20C] Evidence of biomarker modulation indicating potential mechanism of action of LIF inhibition in tumor biopsies from 0201-003. Data show results of pre-h5D8 treatment compared to h5D8 treatment. Figure 20A shows anti-tumor immunity as % change in CD68 frequency; % change in CD8 frequency; and % change in Foxp3 frequency. Figure 20B shows macrophage phenotype characterization as % change in CD163 frequency; % change in CD206 frequency; and % change in MHCII frequency. Figure 20C shows the effect of h5D8 treatment on pSTAT3 as % change in nuclei stained for pSTAT3+. [Figure 21][Figures 21A-21C] Evidence of biomarker modulation indicating potential mechanism of action of LIF inhibition in tumor biopsies from subject 0301-003. Data show results of pre-h5D8 treatment compared to h5D8 treatment. Figure 21A shows anti-tumor immunity as % change in CD68 frequency; % change in CD8 frequency; and % change in Foxp3 frequency. Figure 21B shows macrophage phenotype characterization as % change in CD163 frequency; % change in CD205 frequency; and % change in MHCII frequency. Figure 21C shows the effect of h5D8 treatment on pSTAT3 as % change in nuclei stained for pSTAT3+. [Figure 22] Figure 22 shows evidence of biomarker modulation indicating a potential mechanism of action of LIF inhibition in tumor biopsies from subject 0301-004. Data shows results of pre-h5D8 treatment compared to on h5D8 treatment. Figure 22 shows anti-tumor immunity as % change in CD68 frequency; % change in CD8 frequency; and % change in Foxp3 frequency. [Diagram 23] FIG. 1 shows the LIF stabilization pattern compared to the period of first administration for subject 0201-004. [Figure 24] Figure 24 shows evidence of biomarker modulation indicating a potential mechanism of action of LIF inhibition in tumor biopsies from subject 0201-004. Data shows results of preliminary h5D8 treatment compared to h5D8 treatment. Figure 24 shows macrophage phenotypic characterization as % change in CD163 frequency; % change in CD205 frequency; and % change in MHCII frequency. [Diagram 25] FIG. 13 shows saturation LIF stabilization compared to duration of first dose for subject 0301-002. [Figure 26]Figure 1 shows h5D8 exposure in patients in dose cohorts 1-5. Geometric mean h5D8 plasma levels in patients compared to the start of the first infusion in dose cohorts 1-5 are shown. Additional treatment cycles are shown (mg every 3 weeks). Number of patients analyzed within each cohort were: Cohort 1 n=2, Cohort 2 n=1, Cohort 3 n=10, Cohort 4 n=8 and Cohort 5 n=3. [Figure 27] [Figures 27A-27B] LIF stabilization in patients following treatment with h5D8 in dose cohorts 1-5 compared to the first infusion. Figure 27B shows total LIF levels in patients following the first two cycles of h5D8 in dose cohorts 1-4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Any reference to "or" herein is intended to include "and / or" unless otherwise indicated.
[0012] In one aspect, described herein is a method of treating an individual having cancer, comprising administering to the individual: (a) an immunoglobulin heavy chain complementarity determining region 1 (VH-CDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1-3; (b) an immunoglobulin heavy chain complementarity determining region 2 (VH-CDR2) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 4 or 5; (c) an immunoglobulin heavy chain complementarity determining region 3 (VH-CDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6-8; (d) an immunoglobulin heavy chain complementarity determining region 4 (VH-CDR4) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 9 or 10. and (5) an immunoglobulin light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence set forth in SEQ ID NO: 13; wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg (milligrams).
[0013] In another aspect, described herein is a method of treating an individual having cancer, the method comprising administering to the individual: (a) an immunoglobulin heavy chain variable region (VH) sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 41, 42, 44 or 66, and (b) an immunoglobulin light chain variable region (VL) sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 45-48, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg.
[0014] In another aspect, described herein is a method of treating an individual having cancer, the method comprising administering to the individual: (a) an immunoglobulin heavy chain sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 57-60 or 67, and (b) an immunoglobulin light chain sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 61-64, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg.
[0015] In another aspect, described herein is a pharmaceutical formulation for use in treating cancer in an individual, the pharmaceutical formulation comprising a pharma- ceutical acceptable excipient, carrier, or diluent and a recombinant antibody, the recombinant antibody specifically binds to leukemia inhibitory factor (LIF), and comprises: (a) an immunoglobulin heavy chain complementarity determining region 1 (VH-CDR1) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1-3; (b) an immunoglobulin heavy chain complementarity determining region 2 (VH-CDR2) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 4 or 5; (c) an immunoglobulin heavy chain complementarity determining region 3 (VH-CDR3) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6-8. (d) immunoglobulin light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 9 or 10; (e) immunoglobulin light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 11 or 12; and (f) immunoglobulin light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence set forth in SEQ ID NO: 13, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg.
[0016] In another aspect, described herein is a pharmaceutical formulation for use in treating cancer in an individual, the pharmaceutical formulation comprising a pharma- ceutical acceptable excipient, carrier, or diluent and a recombinant antibody, the recombinant antibody specifically binds leukemia inhibitory factor (LIF), and comprising: (a) an immunoglobulin heavy chain variable region (VH) sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 41, 42, 44, or 66, and (b) an immunoglobulin light chain variable region (VL) sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 45-48, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg.
[0017] In another aspect, described herein is a pharmaceutical formulation for use in treating cancer in an individual, the pharmaceutical formulation comprising a pharma- ceutical acceptable excipient, carrier, or diluent, and a recombinant antibody, the recombinant antibody specifically binds to leukemia inhibitory factor (LIF), and comprising: (a) an immunoglobulin heavy chain sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98%, or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 57-60 or 67, and (b) an immunoglobulin light chain sequence having an amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98%, or 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 61-64, wherein the recombinant antibody is administered to the individual at a dose of about 75 to about 2000 mg.
[0018] Unless otherwise stated, the term "about" is used herein to mean an amount that is at least 10% more or less than the recited amount.
[0019] As used herein, the terms "individual," "subject," and "patient" are used interchangeably and include humans diagnosed with or suspected of suffering from a tumor, cancer, or other neoplasm.
[0020] The term "treat" or "treating" as used herein refers to an intervention in an individual's physiological or disease state that is designed or intended to alleviate at least one sign or symptom associated with said physiological or disease state. Treating or treating with respect to cancers described herein refers to an intervention intended to induce complete remission, partial response, delay in progression of the cancer or tumor being treated, reduction in tumor size or tumor burden, or delay in growth of the tumor or tumor burden. Treating also refers to an intervention intended to reduce metastasis or aggressiveness of the cancer or tumor. Those skilled in the art will recognize that given the heterogeneous population of individuals affected by a disease, not all individuals will respond equally or at all to a given treatment. These individuals are nevertheless considered to be treated. Unsuccessful treatments generally result in disease progression and the need for additional treatments with different therapeutic agents. In certain aspects, the antibodies and methods described herein can be used to maintain remission of a cancer or to prevent recurrence of the same or a different cancer with respect to the cancer that was treated.
[0021] As used herein, "checkpoint inhibitors" refers to drugs that inhibit biological molecules ("checkpoint molecules") produced by the body that negatively regulate the anti-tumor / anti-cancer activity of T cells in the body. Checkpoint molecules can be produced by tumors, immune cells in the tumor microenvironment, or immune cells not present in the tumor microenvironment but present in the bloodstream or lymphatic system. Checkpoint molecules include, without limitation, PD-1, PDL-1, PDL-2, CTLA4, TIM-3, LAG-3, VISTA, SIGLEC7, PVR, TIGIT, IDO, KIR, A2AR, B7-H3, B7H4, and NOX2.
[0022] Unless otherwise stated, the term "antibody" as used herein includes antigen-binding fragments of antibodies, i.e., antibody fragments that maintain the ability to specifically bind to the antigen bound by the full-length antibody, e.g., fragments that maintain one or more CDR regions. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; heavy chain antibodies, single chain antibody molecules, e.g., single chain variable region fragments (scFv), nanobodies, and multispecific antibodies formed from antibody fragments with distinct specificities, e.g., bispecific antibodies. In certain embodiments, the antibody is humanized in a manner that reduces the immune response of an individual to the antibody. For example, the antibody can be chimeric, e.g., a non-human variable region with a human constant region, or a CDR-grafted region, e.g., a non-human CDR region with a human constant region and variable region framework sequences. In certain embodiments, the antibody is deimmunized after humanization. Deimmunization involves removing or mutating one or more T cell epitopes within the constant region of the antibody. In certain embodiments, the antibodies described herein are monoclonal. As used herein, a "recombinant antibody" is an antibody that comprises an amino acid sequence derived from two different species or two different sources, including synthetic molecules, such as antibodies that comprise non-human CDR regions and human framework or constant regions. In certain embodiments, the recombinant antibodies of the invention are generated from recombinant DNA molecules or are synthesized.
[0023] The terms "cancer" and "tumor" refer to a physiological condition in a mammal that is characterized by unregulated cell proliferation. Cancer is a class of diseases in which a group of cells exhibit uncontrolled or unwanted growth. Cancer cells can also spread to other locations, which can result in the formation of metastases. The spread of cancer cells in the body can occur, for example, via lymph or blood. Uncontrolled growth, invasion, and metastasis formation are further referred to as malignant properties of cancer. These malignant properties distinguish cancer from benign tumors, which typically do not invade or metastasize.
[0024] Percent (%) sequence identity compared to a reference polypeptide or antibody sequence is the percentage of amino acid residues in a candidate sequence that are identical to amino acid residues in a reference polypeptide or antibody sequence, after aligning the sequences and introducing gaps, if necessary, to obtain the maximum percent sequence identity and without considering any conservative substitutions as part of the sequence identity. Alignment to determine percent amino acid sequence identity can be accomplished in a variety of ways known in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Appropriate parameters for aligning sequences can be determined, including the algorithm required to achieve the best alignment over the entire length of the sequences being compared. However, for purposes of this specification, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was created by Genentech, Inc., and the source code has been filed with user documentation at the U.S. Copyright Office, Washington DC, 20559, registered under Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available or can be compiled from the source code from Genentech, Inc., South San Francisco, Calif. The ALIGN-2 program must be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
[0025] In the context where ALIGN-2 is used for amino acid sequence comparison, the % amino acid sequence identity of a given amino acid sequence A to a given amino acid sequence B (or it can be said that a given amino acid sequence A has or contains a given % amino acid sequence identity with a given amino acid sequence B) is calculated as follows: 100 times the ratio X / Y, where X is the number of amino acid residues scored as perfect matches by the sequence alignment program ALIGN-2 in the program alignment of A and B, and Y is the total number of amino acid residues in B. It will be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, then the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. Unless otherwise specifically stated, all % amino acid sequence identities used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.
[0026] The term "epitope" includes any determinant that can be bound by an antigen-binding protein, such as an antibody. An epitope is a region of an antigen that is bound by an antigen-binding protein that targets the antigen, and, if the antigen is a protein, includes specific amino acids that directly contact the antigen-binding protein. Most frequently, epitopes are found on proteins, but in some cases, they can also be found on other types of molecules, such as monosaccharides or lipids. Epitopes may include chemically active surface groups of molecules, such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three-dimensional structural characteristics and / or specific charge characteristics. In general, an antibody specific for a particular target antigen will preferentially recognize an epitope on the target antigen in a complex mixture of proteins and / or macromolecules.
[0027] Structural Attributes of the Antibodies Described Herein Complementarity determining regions ("CDRs") are parts of the immunoglobulin (antibody) variable region that are primarily responsible for the antigen-binding specificity of the antibody. The CDR regions are highly variable from one antibody to the next, even when the antibodies specifically bind to the same target or epitope. The heavy chain variable region contains three CDR regions, abbreviated VH-CDR1, VH-CDR2 and VH-CDR3; and the light chain variable region contains three CDR regions, abbreviated VL-CDR1, VL-CDR2 and VL-CDR3. These CDR regions are arranged consecutively within the variable region, with CDR1 being the most N-terminal and CDR3 being the most C-terminal. Interspersed between the CDRs are framework regions that contribute to this structure and present much less variability than the CDR regions. The heavy chain variable region comprises four framework regions, abbreviated as VH-FR1, VH-FR2, VH-FR3 and VH-FR4; and the light chain variable region comprises four framework regions, abbreviated as VL-FR1, VL-FR2, VL-FR3 and VL-FR4. A complete full-length size bivalent antibody comprising two heavy and light chains comprises: 12 CDRs, comprising three unique heavy chain CDRs and three unique light chain CDRs; 16 FR regions, comprising four unique heavy chain FR regions and four unique light chain FR regions. In certain embodiments, the antibodies described herein comprise a minimum of three heavy chain CDRs. In certain embodiments, the antibodies described herein comprise a minimum of three light chain CDRs. In certain embodiments, the antibodies described herein comprise a minimum of three heavy chain CDRs and three light chain CDRs.The precise amino acid sequence boundaries of a given CDR or FR can be determined by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (the “Kabat” numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 (the “Chothia” numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” (the “Contact” numbering scheme); Lefranc MP et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol, 2003 Jan;27(1):55-77 ("IMGT" numbering scheme); and Honegger A and Plueckthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," J Mol Biol, 2001 Jun 8;309(3):657-70, ("Aho" numbering scheme). CDRs are identified from the variable sequences provided herein using various numbering systems, herein the Kabat, IMGT, Chothia numbering systems, or any combination of the three. The boundaries of a given CDR or FR may vary depending on the scheme used for identification.For example, the Kabat scheme is based on structural alignment, while the Chothia scheme is based on structural information. The numbering for both the Kabat and Chothia schemes is based on the most common antibody region sequence length, with insertions and deletions occurring in some antibodies accompanied by an insertion letter, e.g., "30a". These two schemes place certain insertions and deletions ("indels") at different positions, resulting in different numbering. The Contact scheme is based on the analysis of complex crystal structures and is similar in many aspects to the Chothia numbering scheme. In certain embodiments, the CDRs can be defined by any combination of the IMGT, Chothia, Kabat, Contact, and Aho methods.
[0028] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have a similar structure, with each domain containing four conserved framework regions (FR) and three CDRs (see, for example, Kindt et al. Kuby Immunology, 6th ed., WH Freeman and Co., page 91 (2007)). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind to a specific antigen can be isolated from antibodies that bind to the antigen using a VH or VL domain to screen a library of complementary VL or VH domains, respectively (see, for example, Portolano et al., J. Immunol. 150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991)). In certain embodiments, the antibodies described herein comprise variable regions of rat origin. In certain embodiments, the antibodies described herein comprise CDRs of rat origin. In certain embodiments, the antibodies described herein comprise variable regions of mouse origin. In certain embodiments, the antibodies described herein comprise CDRs of mouse origin.
[0029] For example, changes (e.g., substitutions) can be made in CDRs to improve antibody affinity. Such changes can be made in CDRs that code for codons with high mutation rates during somatic maturation (see, e.g., Chowdhury, Methods Mol. Biol. 207:179-196 (2008)), and the resulting mutants can be tested for binding affinity. Affinity maturation (e.g., using error-prone PCR, chain shuffling, CDR randomization, or oligonucleotide-directed mutagenesis) can be used to improve antibody affinity (see, e.g., Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (2001)). CDR residues involved in antigen binding can be specifically identified using, e.g., alanine scanning mutagenesis or modeling (see, e.g., Cunningham and Wells Science, 244:1081-1085 (1989)). CDR-H3 and CDR-L3 in particular are frequently targeted. Alternatively, or in addition, a crystal structure of the antigen-antibody complex is analyzed to identify contact points between the antibody and the antigen. Such contact and adjacent residues can be targeted or eliminated as candidates for substitution. Mutants can be screened to determine whether they contain the desired properties.
[0030] In certain embodiments, the antibodies described herein comprise a constant region in addition to the variable region. H ) is located at the C-terminus of the full-length heavy chain polypeptide, which is the C-terminus of the variable region, H 1. C H 2. C H 3 and C H It contains four domains, abbreviated as C4. The light chain constant region (C L ) is C HThe constant regions are much smaller than the variable regions and are located at the C-terminus of the full-length light chain polypeptide, C-terminal to the variable regions. The constant regions are highly conserved and include a variety of isotypes that are associated with slightly different functions and properties. In certain embodiments, the constant regions are not essential for an antibody to bind to a target antigen. In certain embodiments, the constant regions of an antibody, both the heavy and light chains, are not essential for antibody binding. In certain embodiments, the antibodies described herein lack one or more of the light chain constant regions, the heavy chain constant regions, or both. The majority of monoclonal antibodies are further divided into four subclasses, IgG 1 , IgG 2 , IgG 3 and IgG 4 In certain embodiments, the antibodies described herein comprise any IgG subclass. In certain embodiments, the IgG subclass is an IgG 1 In certain embodiments, the IgG subclass comprises IgG 2 In certain embodiments, the IgG subclass comprises IgG 3 In certain embodiments, the IgG subclass comprises IgG 4 Includes.
[0031] Antibodies contain a fragment crystallizable region (Fc region) that is responsible for binding to complement and Fc receptors. The Fc region is the C region of the antibody molecule. H 2. C H 3 and C HThe Fc region of an antibody comprises four regions. The Fc region of an antibody is responsible for activating complement and antibody-dependent cellular cytotoxicity (ADCC). The Fc region further contributes to the serum half-life of the antibody. In certain embodiments, the Fc region of an antibody described herein comprises one or more amino acid substitutions that promote complement-mediated cell lysis. In certain embodiments, the Fc region of an antibody described herein comprises one or more amino acid substitutions that promote ADCC. In certain embodiments, the Fc region of an antibody described herein comprises one or more amino acid substitutions that decrease complement-mediated cell lysis. In certain embodiments, the Fc region of an antibody described herein comprises one or more amino acid substitutions that increase binding of the antibody to an Fc receptor. In certain embodiments, the Fc receptor comprises FcγRI (CD64), FcγRIIA (CD32), FcγRIIIA (CD16a), FcγRIIIB (CD16b), or any combination thereof. In certain embodiments, the Fc region of an antibody described herein comprises one or more amino acid substitutions that increase the serum half-life of the antibody. In certain embodiments, the one or more amino acid substitutions that increase the serum half-life of the antibody increase the affinity of the antibody for the neonatal Fc receptor (FcRn).
[0032] In some embodiments, the antibodies of the present disclosure are mutants that have some, but not all, effector functions that make them desirable candidates for applications where in vivo antibody half-life is important, yet certain effector functions (such as complement and ADCC) are unnecessary or detrimental. In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduced / depleted CDC and / or ADCC activity. For example, Fc receptor (FcR) binding assays can be performed to confirm that the antibody lacks FcγR binding (and thus likely lacks ADCC activity), but maintains FcRn binding ability. Non-limiting examples of in vitro assays for assessing ADCC activity of molecules of interest are described in U.S. Patent Nos. 5,500,362 and 5,821,337. Alternatively, non-radioactive assay methods (e.g., ACTI™ and CytoTox 96® non-radioactive cytotoxicity assays) can be used. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC), monocytes, macrophages and natural killer (NK) cells.
[0033] The antibodies may have increased half-life and improved binding to the neonatal Fc receptor (FcRn) (see, e.g., U.S. Patent Application Publication No. 2005 / 0014934). Such antibodies may include an Fc region with one or more substitutions therein that improve binding of the Fc region to FcRn, and may include those Fc regions with substitutions at one or more Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, or 434 according to the EU numbering system (see, e.g., U.S. Patent No. 7,371,826). Other examples of Fc region variants are also contemplated (see, e.g., Duncan & Winter, Nature 322:738-40 (1988); U.S. Pat. Nos. 5,648,260 and 5,624,821; and WO 94 / 29351).
[0034] Clinically useful antibodies are often "humanized" to reduce immunogenicity in human individuals. Humanized antibodies improve the safety and efficacy of monoclonal antibody therapy. One common method of humanization is to generate a monoclonal antibody in any suitable animal (e.g., mouse, rat, hamster) and replace the constant region with a human constant region; antibodies modified in this manner are called "chimeric." Another common method is "CDR grafting," in which non-human V-FRs are replaced with human V-FRs. In the CDR grafting method, all residues except the CDR regions are of human origin. In certain embodiments, the antibodies described herein are humanized. In certain embodiments, the antibodies described herein are chimeric. In certain embodiments, the antibodies described herein are CDR grafted.
[0035] Humanization generally reduces or has little effect on the overall affinity of an antibody. Described herein are antibodies that have unexpectedly greater affinity for their target after humanization. In some embodiments, humanization increases affinity for the antibody by 10%. In some embodiments, humanization increases affinity for the antibody by 25%. In some embodiments, humanization increases affinity for the antibody by 35%. In some embodiments, humanization increases affinity for the antibody by 50%. In some embodiments, humanization increases affinity for the antibody by 60%. In some embodiments, humanization increases affinity for the antibody by 75%. In some embodiments, humanization increases affinity for the antibody by 100%. Affinity is suitably measured using surface plasmon resonance (SPR). In some embodiments, affinity is measured using glycosylated human LIF. In some embodiments, glycosylated human LIF is immobilized on the surface of an SPR chip. In certain embodiments, the antibody has a K of less than about 300 nanomolar, 200 nanomolar, 150 nanomolar, 125 nanomolar, 100 nanomolar, 90 nanomolar, 80 nanomolar, 70 nanomolar, 60 nanomolar, 50 nanomolar, 40 nanomolar. D Combine with.
[0036] Antibodies of the present disclosure The antibodies described herein were generated from rats immunized with DNA encoding human LIF.
[0037] In certain embodiments, described herein is an antibody (5D8) that specifically binds to LIF comprising a VH-CDR1 set forth in any one of SEQ ID NOs: 1-3, a VH-CDR2 set forth in any one of SEQ ID NOs: 4 or 5, and a VH-CDR3 set forth in any one of SEQ ID NOs: 6-8. In certain embodiments, described herein is an antibody that specifically binds to LIF comprising a VL-CDR1 set forth in any one of SEQ ID NOs: 9 or 10, a VL-CDR2 set forth in SEQ ID NOs: 11 or 12, and a VL-CDR3 set forth in SEQ ID NO: 13. In certain embodiments, described herein is an antibody that specifically binds to LIF, comprising a VH-CDR1 set forth in any one of SEQ ID NOs: 1-3, a VH-CDR2 set forth in any one of SEQ ID NOs: 4 or 5, and a VH-CDR3 set forth in any one of SEQ ID NOs: 6-8, a VL-CDR1 set forth in any one of SEQ ID NOs: 9 or 10, a VL-CDR2 set forth in SEQ ID NOs: 11 or 12, and a VL-CDR3 set forth in SEQ ID NO: 13. In certain embodiments, the antibody specifically binds to human LIF.
[0038] In certain embodiments, an antibody that specifically binds to LIF comprises one or more human heavy chain framework regions comprising: a VH-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 14-17; a VH-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 18 or 19; a VH-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 20-22; or a VH-FR4 region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 23-25. In certain embodiments, the one or more human heavy chain framework regions comprise a VH-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:15, a VH-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:19, a VH-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:20, and a VH-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:24.In certain embodiments, an antibody that specifically binds to LIF comprises one or more human light chain framework regions comprising: a VL-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 26-29; a VL-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 30-33; a VL-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 34-37; or a VL-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 38-40. In certain embodiments, the one or more human light chain framework regions comprise a VL-FR1 amino acid sequence that is at least about 80%, 90%, or 95% identical to the amino acid sequence set forth in SEQ ID NO:27, a VL-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:31, a VL-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:35, and a VL-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:38.In certain embodiments, the one or more human heavy chain framework regions and the one or more human light chain regions comprise a VH-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 15, a VH-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 19, a VH-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 20, a VH-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 24, a VH-FR5 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 25, a VH-FR6 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 26, a VH-FR7 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 27, a VH-FR8 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 28, a VH-FR9 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 9 a VH-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:27; a VL-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:31; a VL-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:35; and a VL-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:38. In certain embodiments, an antibody that specifically binds to LIF comprises one or more human heavy chain framework regions comprising: a VH-FR1 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 14-17, a VH-FR2 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 18 or 19, a VH-FR3 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 20-22, or a VH-FR4 region amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 23-25. In certain embodiments, the one or more human heavy chain framework regions comprise a VH-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 15, a VH-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 19, a VH-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 20, and a VH-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 24.In certain embodiments, an antibody that specifically binds to LIF comprises one or more human light chain framework regions comprising: a VL-FR1 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 26-29, a VL-FR2 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 30-33, a VL-FR3 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 34-37, or a VL-FR4 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 38-40. In certain embodiments, the one or more human light chain framework regions comprise a VL-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 27, a VL-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 31, a VL-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 35, and a VL-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 38. In certain embodiments, the one or more human heavy chain framework regions and the one or more human light chain regions comprise a VH-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 15, a VH-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 19, a VH-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 20, a VH-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 24, a VL-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 27, a VL-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 31, a VL-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 35, and a VL-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 38. In certain embodiments, the antibody specifically binds human LIF.
[0039] 5D8 The antibodies described herein were generated from rats immunized with DNA encoding human LIF. One such antibody (5D8) was cloned and sequenced (using a combination of Kabat and IMGT CDR numbering systems) and contains CDRs including the following amino acid sequence: VH-CDR1 corresponding to SEQ ID NO: 1 (GFTFSHAWMH), VH-CDR2 corresponding to SEQ ID NO: 4 (QIKAKSDDYATYYAESVKG), VH-CDR3 corresponding to SEQ ID NO: 6 (TCWEWDLDF), VL-CDR1 corresponding to SEQ ID NO: 9 (RSSQSLLDSDGHTYLN), VL-CDR2 corresponding to SEQ ID NO: 11 (SVSNLES) and VL-CDR3 corresponding to SEQ ID NO: 13 (MQATHAPPYT). This antibody has been humanized by CDR grafting and the humanized version is referred to as h5D8.
[0040] In certain embodiments, described herein are antibodies that specifically bind to LIF comprising a VH-CDR1 that is at least 80% or 90% identical to that set forth in SEQ ID NO:1 (GFTFSHAWMH), a VH-CDR2 that is at least 80%, 90% or 95% identical to that set forth in SEQ ID NO:4 (QIKAKSDDYATYYAESVKG), and a VH-CDR3 that is at least 80% or 90% identical to that set forth in SEQ ID NO:6 (TCWEWDLDF). In certain embodiments, described herein are antibodies that specifically bind to LIF comprising a VL-CDR1 that is at least 80% or 90% identical to that set forth in SEQ ID NO:9 (RSSQSLLDSDGHTYLN), a VL-CDR2 that is at least 80% identical to that set forth in SEQ ID NO:11 (SVSNLES), and a VL-CDR3 that is at least 80% or 90% identical to that set forth in SEQ ID NO:13 (MQATHAPPYT). In certain embodiments, described herein are antibodies that specifically bind to an ILF comprising a VH-CDR1 set forth in SEQ ID NO: 1 (GFTFSHAWMH), a VH-CDR2 set forth in SEQ ID NO: 4 (QIKAKSDDYATYYAESVKG), a VH-CDR3 set forth in SEQ ID NO: 6 (TCWEWDLDF), a VL-CDR1 set forth in SEQ ID NO: 9 (RSSQSLLDSDGHTYLN), a VL-CDR2 set forth in SEQ ID NO: 11 (SVSNLES), and a VL-CDR3 set forth in SEQ ID NO: 13 (MQATHAPPYT). Certain conservative amino acid substitutions are contemplated in the amino acid sequences of the CDRs of the present disclosure. In certain embodiments, the antibody comprises a CDR that differs by 1, 2, 3, or 4 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 6, 9, 11, and 13. In some embodiments, the antibody comprises a CDR that differs from the amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 6, 9, 11, and 13 by 1, 2, 3, or 4 amino acids that do not affect binding affinity by more than 10%, more than 20%, or more than 30%.In certain embodiments, an antibody that specifically binds to LIF comprises one or more human heavy chain framework regions comprising: a VH-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 14-17; a VH-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 18 or 19; a VH-FR3 amino acid sequence that is at least 90% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 20-22; or a VH-FR4 region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 23-25. In certain embodiments, the one or more human heavy chain framework regions comprise a VH-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:15, a VH-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:19, a VH-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:20, and a VH-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:24. In certain embodiments, an antibody that specifically binds to LIF comprises one or more human light chain framework regions comprising: a VL-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 26-29; a VL-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 30-33; a VL-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 34-37; or a VL-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 38-40.In certain embodiments, the one or more human light chain framework regions comprise a VL-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:27, a VL-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:31, a VL-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:35, and a VL-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:38. In certain embodiments, the one or more human heavy chain framework regions and the one or more human light chain regions comprise a VH-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:15, a VH-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:19, a VH-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:20, a VH-FR4 amino acid sequence that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO:24, or a VH-FR5 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:25, or a VH-FR6 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:26, or a VH-FR7 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:27, or a VH-FR8 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:28, or a VH-FR9 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:29, or and a VL-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 38. In certain embodiments, the antibody specifically binds to human LIF.In certain embodiments, an antibody that specifically binds to LIF comprises one or more human heavy chain framework regions comprising: a VH-FR1 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 14-17, a VH-FR2 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 18 or 19, a VH-FR3 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 20-22, or a VH-FR4 region amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 23-25. In certain embodiments, the one or more human heavy chain framework regions comprise a VH-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 15, a VH-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 19, a VH-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 20, and a VH-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 24. In certain embodiments, an antibody that specifically binds to LIF comprises one or more human light chain framework regions comprising: a VL-FR1 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 26-29, a VL-FR2 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 30-33, a VL-FR3 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 34-37, or a VL-FR4 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 38-40. In certain embodiments, the one or more human light chain framework regions comprise a VL-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 27, a VL-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 31, a VL-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 35, and a VL-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 38.In certain embodiments, the one or more human heavy chain framework regions and the one or more human light chain regions comprise a VH-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 15, a VH-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 19, a VH-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 20, a VH-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 24, a VL-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 27, a VL-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 31, a VL-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 35, and a VL-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 38. In certain embodiments, the antibody specifically binds human LIF.
[0041] In certain embodiments, described herein are antibodies that specifically bind to LIF comprising a VH-CDR1 amino acid sequence that is at least 80% or 90% identical to that set forth in SEQ ID NO:1 (GFTFSHAWMH), a VH-CDR2 amino acid sequence that is at least 80%, 90% or 95% identical to that set forth in SEQ ID NO:4 (QIKAKSDDYATYYAESVKG), and a VH-CDR3 amino acid sequence that is at least 80% or 90% identical to that set forth in SEQ ID NO:8 (TSWEWDLDF). In certain embodiments, described herein are antibodies that specifically bind to LIF comprising: a VL-CDR1 amino acid sequence that is at least 80% or 90% identical to the amino acid sequence set forth in SEQ ID NO:9 (RSSQSLLDSDGHTYLN), a VL-CDR2 amino acid sequence that is at least 80% identical to the amino acid sequence set forth in SEQ ID NO:11 (SVSNLES), and a VL-CDR3 amino acid sequence that is at least 80% or 90% identical to the amino acid sequence set forth in SEQ ID NO:13 (MQATHAPPYT). In certain embodiments, described herein is an antibody that specifically binds to LIF comprising: a VH-CDR1 amino acid sequence set forth in SEQ ID NO:1 (GFTFSHAWMH), a VH-CDR2 amino acid sequence set forth in SEQ ID NO:4 (QIKAKSDDYATYYAESVKG), a VH-CDR3 amino acid sequence set forth in SEQ ID NO:8 (TSWEWDLDF), a VL-CDR1 amino acid sequence set forth in SEQ ID NO:9 (RSSQSLLDSDGHTYLN), a VL-CDR2 amino acid sequence set forth in SEQ ID NO:11 (SVSNLES), and a VL-CDR3 amino acid sequence set forth in SEQ ID NO:13 (MQATHAPPYT). Certain conservative amino acid substitutions are contemplated in the amino acid sequences of the CDRs of the disclosure. In certain embodiments, the antibody comprises a CDR that differs by 1, 2, 3, or 4 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs:1, 4, 8, 9, 11, and 13. In certain embodiments, the antibody comprises a CDR that differs from the amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 8, 9, 11, and 13 by 1, 2, 3, or 4 amino acids that do not affect binding affinity by more than 10%, more than 20%, or more than 30%.In certain embodiments, an antibody that specifically binds to LIF comprises one or more human heavy chain framework regions comprising: a VH-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 14-17; a VH-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 18 or 19; a VH-FR3 amino acid sequence that is at least 90% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 20-22; or a VH-FR4 region amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 23-25. In certain embodiments, the one or more human heavy chain framework regions comprise a VH-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:15, a VH-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:19, a VH-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:20, and a VH-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:24. In certain embodiments, an antibody that specifically binds to LIF comprises one or more human light chain framework regions comprising: a VL-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 26-29; a VL-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 30-33; a VL-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 34-37; or a VL-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 38-40.In certain embodiments, the one or more human light chain framework regions comprise a VL-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:27, a VL-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:31, a VL-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:35, and a VL-FR4 amino acid sequence that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO:38. In certain embodiments, the one or more human heavy chain framework regions and the one or more human light chain regions comprise a VH-FR1 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:15, a VH-FR2 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:19, a VH-FR3 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:20, a VH-FR4 amino acid sequence that is at least 90% identical to the amino acid sequence set forth in SEQ ID NO:24, or a VH-FR5 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:25, or a VH-FR6 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:26, or a VH-FR7 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:27, or a VH-FR8 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:28, or a VH-FR9 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:29, or and a VL-FR4 amino acid sequence that is at least about 80%, 90%, 95%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 38. In certain embodiments, the antibody specifically binds to human LIF.In certain embodiments, an antibody that specifically binds to LIF comprises one or more human heavy chain framework regions comprising: a VH-FR1 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 14-17, a VH-FR2 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 18 or 19, a VH-FR3 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 20-22, or a VH-FR4 region amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 23-25. In certain embodiments, the one or more human heavy chain framework regions comprise a VH-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 15, a VH-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 19, a VH-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 20, and a VH-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 24. In certain embodiments, an antibody that specifically binds to LIF comprises one or more human light chain framework regions comprising: a VL-FR1 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 26-29, a VL-FR2 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 30-33, a VL-FR3 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 34-37, or a VL-FR4 amino acid sequence identical to the amino acid sequence set forth in any one of SEQ ID NOs: 38-40. In certain embodiments, the one or more human light chain framework regions comprise a VL-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 27, a VL-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 31, a VL-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 35, and a VL-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 38.In certain embodiments, the one or more human heavy chain framework regions and the one or more human light chain regions comprise a VH-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 15, a VH-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 19, a VH-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 20, a VH-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 24, a VL-FR1 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 27, a VL-FR2 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 31, a VL-FR3 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 35, and a VL-FR4 amino acid sequence identical to the amino acid sequence set forth in SEQ ID NO: 38. In certain embodiments, the antibody specifically binds human LIF.
[0042] In certain embodiments, described herein are antibodies that specifically bind to LIF comprising a humanized heavy chain variable region comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98%, or about 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 41, 42, and 44. In certain embodiments, described herein are antibodies that specifically bind to LIF comprising a humanized heavy chain variable region comprising an amino acid sequence set forth in any one of SEQ ID NOs: 41, 42, and 44. In certain embodiments, described herein are antibodies that specifically bind to LIF comprising a humanized light chain variable region comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98%, or about 99% identical to an amino acid sequence set forth in any one of SEQ ID NOs: 45-48. In certain embodiments, described herein are antibodies that specifically bind to LIF comprising a humanized light chain variable region comprising an amino acid sequence set forth in any one of SEQ ID NOs: 45-48. In certain embodiments, the antibody specifically binds to human LIF.
[0043] In certain embodiments, described herein are antibodies that specifically bind to LIF comprising: a humanized heavy chain variable region comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 42, and a humanized light chain variable region comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 46. In certain embodiments, described herein are antibodies that specifically bind to LIF comprising a humanized heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 42, and a humanized light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 46.
[0044] In certain embodiments, described herein are antibodies that specifically bind to LIF comprising: a humanized heavy chain variable region comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 66, and a humanized light chain variable region comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 46. In certain embodiments, described herein are antibodies that specifically bind to LIF comprising a humanized heavy chain variable region comprising an amino acid sequence set forth in SEQ ID NO: 66, and a humanized light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 46.
[0045] In certain embodiments, described herein is an antibody that specifically binds to LIF comprising: a humanized heavy chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98%, or about 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 57-60, and a humanized light chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98%, or about 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 61-64. In certain embodiments, described herein is an antibody that specifically binds to LIF comprising a humanized heavy chain comprising an amino acid sequence set forth in any one of SEQ ID NOs: 57-60, and a humanized light chain comprising the amino acid sequence set forth in any one of SEQ ID NOs: 61-64.
[0046] In certain embodiments, described herein is an antibody that specifically binds to LIF comprising: a humanized heavy chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 58, and a humanized light chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 62. In certain embodiments, described herein is an antibody that specifically binds to LIF comprising a humanized heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 58, and a humanized light chain comprising the amino acid sequence set forth in SEQ ID NO: 62. In certain embodiments, described herein is an antibody that specifically binds to LIF comprising: a humanized heavy chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 67, and a humanized light chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 62. In certain embodiments, described herein is an antibody that specifically binds to LIF comprising a humanized heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 67, and a humanized light chain comprising the amino acid sequence set forth in SEQ ID NO: 62.
[0047] In certain embodiments, described herein is a recombinant antibody that specifically binds to leukemia inhibitory factor (LIF), comprising: a heavy chain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence set forth in SEQ ID NO:3; a heavy chain complementarity determining region 2 (VH-CDR2) comprising the amino acid sequence set forth in SEQ ID NO:4; a heavy chain complementarity determining region 3 (VH-CDR3) comprising the amino acid sequence set forth in SEQ ID NO:7; a light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence set forth in SEQ ID NO:9; and a light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence set forth in SEQ ID NO:11, and a light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence set forth in SEQ ID NO:13.
[0048] In certain embodiments, described herein is a recombinant antibody that specifically binds to leukemia inhibitory factor (LIF) comprising: heavy chain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence set forth in SEQ ID NO:2; heavy chain complementarity determining region 2 (VH-CDR2) comprising the amino acid sequence set forth in SEQ ID NO:5; heavy chain complementarity determining region 3 (VH-CDR3) comprising the amino acid sequence set forth in SEQ ID NO:6; light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence set forth in SEQ ID NO:10; and light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence set forth in SEQ ID NO:12; and light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence set forth in SEQ ID NO:13. Certain conservative amino acid substitutions are contemplated in the amino acid sequences of the CDRs of the present disclosure. In certain embodiments, the antibody comprises a CDR that differs by 1, 2, 3 or 4 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs:2, 5, 6, 10, 12 and 13. In certain embodiments, the antibody comprises a CDR that differs by 1, 2, 3 or 4 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs: 2, 5, 6, 10, 12 and 13 and that does not affect binding affinity by more than 10%, more than 20%, or more than 30%.
[0049] In certain embodiments, described herein is a recombinant antibody that specifically binds to leukemia inhibitory factor (LIF) comprising: heavy chain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence set forth in SEQ ID NO:3; heavy chain complementarity determining region 2 (VH-CDR2) comprising the amino acid sequence set forth in SEQ ID NO:4; heavy chain complementarity determining region 3 (VH-CDR3) comprising the amino acid sequence set forth in SEQ ID NO:7; light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence set forth in SEQ ID NO:9; and light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence set forth in SEQ ID NO:11 and light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence set forth in SEQ ID NO:13. Certain conservative amino acid substitutions are contemplated in the amino acid sequences of the CDRs of the present disclosure. In certain embodiments, the antibody comprises a CDR that differs by 1, 2, 3 or 4 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs:3, 4, 7, 9, 11 and 13. In some embodiments, the antibody comprises a CDR that differs by 1, 2, 3 or 4 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs: 3, 4, 7, 9, 11 and 13 and that does not affect binding affinity by more than 10%, more than 20%, or more than 30%.
[0050] In certain embodiments, described herein is an antibody that specifically binds to LIF comprising: a humanized heavy chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98%, or about 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 49-52, and a humanized light chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98%, or about 99% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 53-56. In certain embodiments, described herein is an antibody that specifically binds to LIF comprising a humanized heavy chain comprising an amino acid sequence set forth in any one of SEQ ID NOs: 49-52, and a humanized light chain comprising the amino acid sequence set forth in any one of SEQ ID NOs: 53-56.
[0051] In certain embodiments, described herein is an antibody that specifically binds to LIF comprising: a humanized heavy chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 50, and a humanized light chain comprising an amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 54. In certain embodiments, described herein is an antibody that specifically binds to LIF comprising a humanized heavy chain comprising an amino acid sequence set forth in SEQ ID NO: 50, and a humanized light chain comprising an amino acid sequence set forth in any one of SEQ ID NOs: 54.
[0052] Therapeutically useful epitopes bound by LIF antibodies Described herein are unique epitopes of human LIF that upon binding inhibit LIF biological activity (e.g., STAT3 phosphorylation) and inhibit tumor growth in vivo. The epitopes described herein consist of two non-contiguous stretches of amino acids (residues 13-32 and residues 120-138 of human LIF) present in two distinct topological domains (alpha helices A and C) of the human LIF protein. The binding is a weak (van der Waals attraction), intermediate (hydrogen bond) and strong (salt bridge) interaction. In certain embodiments, contact residues are residues on LIF that form hydrogen bonds with residues on the anti-LIF antibody. In certain embodiments, contact residues are residues on LIF that form salt bridges with residues on the anti-LIF antibody. In certain embodiments, contact residues are residues on LIF that create van der Waals attraction and that are at least 5, 4 or 3 angstroms (Å) and within at least 5, 4 or 3 Å of residues in the anti-LIF antibody.
[0053] In certain embodiments, described herein are isolated antibodies that comprise a CDR that binds to any one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO:68. In certain embodiments, described herein are isolated antibodies that bind to all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In certain embodiments, described herein are isolated antibodies that bind to all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In certain embodiments, the antibody binds only to residues that participate in strong or intermediate interactions with the antibody. In certain embodiments, the antibody binds only to residues that participate in strong interactions with the antibody. In certain embodiments, the antibody interacts with helices A and C of LIF. In certain embodiments, the antibody blocks LIF interaction with gp130.
[0054] In certain embodiments, described herein are antibodies comprising a CDR comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 6, 9, 11, and 13 that binds to any one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, nine, or twenty of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO:68. In certain embodiments, described herein are antibodies comprising a CDR comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 6, 9, 11, and 13 that binds to all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO:68. In certain embodiments, the antibody binds only to residues that participate in strong or intermediate interactions with the antibody. In certain embodiments, the antibody binds only to residues that participate in strong interactions with the antibody.
[0055] In certain embodiments, described herein are antibodies comprising a CDR comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 8, 9, 11, and 13 that binds to any one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, nine, or twenty of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO:68. In certain embodiments, described herein are antibodies comprising a CDR comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 8, 9, 11, and 13 that binds to all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In certain embodiments, the antibody binds only to residues that participate in strong or intermediate interactions with the antibody. In certain embodiments, the antibody binds only to residues that participate in strong interactions with the antibody.
[0056] In certain embodiments, described herein are antibodies that differ by 1, 2, 3, 4 or 5 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 6, 9, 11, and 13, and that contain CDRs that bind to any one, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO:68. In certain embodiments, described herein are antibodies that differ by 1, 2, 3, 4, or 5 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 6, 9, 11, and 13, and that contain CDRs that bind all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In certain embodiments, the antibody binds only to residues that participate in strong or intermediate interactions with the antibody. In certain embodiments, the antibody binds only to residues that participate in strong interactions with the antibody.
[0057] In certain embodiments, described herein are antibodies that differ by 1, 2, 3, 4 or 5 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 8, 9, 11, and 13, and that contain CDRs that bind to any one, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO:68. In certain embodiments, described herein are antibodies that differ by 1, 2, 3, 4, or 5 amino acids from the amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, 8, 9, 11, and 13, and that contain CDRs that bind all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135, or H138 of SEQ ID NO: 68. In certain embodiments, the antibody binds only to residues that participate in strong or intermediate interactions with the antibody. In certain embodiments, the antibody binds only to residues that participate in strong interactions with the antibody.
[0058] In certain embodiments, described herein is a LIF comprising: a humanized heavy chain variable region amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO:42; and a humanized light chain variable region amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO:46. and binds to any one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, seven, eight, nine, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, seven, eight, nine, nine, ten, In certain embodiments, described herein are antibodies that specifically bind LIF comprising a humanized heavy chain variable region amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 42 and a humanized light chain variable region amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 46, and that bind to all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135 or H138 of SEQ ID NO: 68. In certain embodiments, the antibody binds only to residues that participate in strong or intermediate interactions with the antibody. In certain embodiments, the antibody binds only to residues that participate in strong interactions with the antibody.
[0059] In certain embodiments, described herein is a LIF comprising: a humanized heavy chain variable region amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO:66; and a humanized light chain variable region amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO:46. and binds to any one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, seven, eight, nine, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, seven, eight, nine, nine, ten, In certain embodiments, described herein are antibodies that specifically bind LIF comprising a humanized heavy chain variable region amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 66 and a humanized light chain variable region amino acid sequence that is at least about 80%, about 90%, about 95%, about 97%, about 98% or about 99% identical to the amino acid sequence set forth in SEQ ID NO: 46, and bind to all of the following residues: A13, I14, R15, H16, P17, C18, H19, N20, Q25, Q29, Q32, D120, R123, S127, N128, L130, C131, C134, S135 or H138 of SEQ ID NO: 68. In certain embodiments, the antibody binds only to residues that participate in strong or intermediate interactions with the antibody. In certain embodiments, the antibody binds only to residues that participate in strong interactions with the antibody.
[0060] Treatment indications In certain embodiments, the antibodies disclosed herein inhibit LIF signaling in cells. In certain embodiments, the IC for biological inhibition of the antibodies under serum starvation conditions in U-251 cells is 50 In certain embodiments, the IC for biological inhibition of the antibody under serum-starved conditions in U-251 cells is about 100, 75, 50, 40, 30, 20, 10, 5, or 1 nanomolar or less.50 is less than about 900, 800, 700, 600, 500, 400, 300, 200 or 100 nanomolar.
[0061] In some embodiments, the h5D8 and doses of h5D8 described herein are useful for treating tumors and cancers that express LIF. In some embodiments, individuals treated with the antibodies of the present disclosure have been selected for treatment as having a LIF-positive tumor / cancer. In some embodiments, the tumor is LIF-positive or produces high levels of LIF. In some embodiments, LIF positivity is determined relative to a reference value or a defined pathological criterion. In some embodiments, a LIF-positive tumor expresses more than 2-fold, more than 3-fold, more than 5-fold, more than 10-fold, 100-fold or more LIF than the non-transformed cells from which the tumor originates. In some embodiments, the tumor has acquired ectopic expression of LIF. LIF-positive tumors can be determined histologically, for example, using immunohistochemistry (IHC) with anti-LIF antibodies; by commonly used molecular biology methods, such as mRNA quantification, for example, real-time PCR or RNA-seq; or by protein quantification, for example, by Western blot, flow cytometry, ELISA, or homogeneous protein quantification assays (e.g., AlphaLISA®). In certain embodiments, the antibodies can be used to treat patients diagnosed with cancer. In certain embodiments, the cancer comprises or is one or more cancer stem cells.
[0062] In some embodiments, h5D8 and doses of h5D8 described herein are useful for treating tumors in cancers that express LIF receptor (CD118). LIF receptor positive tumors can be determined histologically or by flow cytometry, and in some embodiments, contain cells that bind to LIF receptor antibodies that are 2-fold, 3-fold, 4-fold, 5-fold, 10-fold greater than isotype controls. In some embodiments, the tumor has acquired ectopic expression of LIF receptor. In some embodiments, the cancer is a cancer stem cell. In some embodiments, LIF positive tumors or cancers can be determined by immunohistology (IHC) using anti-LIF anti-LIF antibodies. In some embodiments, LIF positive tumors are determined by IHC analysis using LIF levels in the top 10%, 20%, 30%, 40%, or top 50% of tumors.
[0063] The h5D8 and doses of h5D8 described herein affect a number of outcomes. In certain embodiments, the antibodies described herein can reduce the presence of M2 macrophages in tumors in tumor models by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to a control antibody (e.g., an isotype control). M2 macrophages can be identified by staining for CCL22 and / or CD206 in IHC sections or by flow cytometry of tumor-infiltrating immune cells or myeloid cells. In certain embodiments, the antibodies described herein can reduce LIF binding to gp130 tumors by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to a control antibody (e.g., an isotype control). In certain embodiments, the antibodies described herein can reduce LIF signaling in a LIF-responsive cell line by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to a control antibody (e.g., an isotype control). LIF signaling can be measured, for example, by Western blot for phosphorylated STAT3 (a downstream target of LIF signaling). The antibodies herein are also highly specific for LIF compared to other IL-6 family member cytokines. In certain embodiments, the antibodies bind to human LIF with an affinity that is about 10-fold, about 50-fold, or about 100-fold greater than the affinity of any other IL-6 family member cytokine. In certain embodiments, the LIF antibodies do not bind to other IL-6 family member cytokines produced in a mammalian system. In certain embodiments, the antibodies do not bind to Oncostatin M produced in a mammalian system.
[0064] The h5D8 and doses of h5D8 described herein are useful in methods for improving the levels of biomarkers that are prognostic indicators of tumor or cancer burden. Tumor markers such as carbohydrate antigen-125 (CA-125), carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) are positive prognostic indicators. Generally, low levels of these antigens correlate with successful treatment. In certain embodiments, h5D8, when administered about once every other week, every three weeks or every four weeks at a dose of about 1125 or 1500, including escalations therein, reduces serum CEA, CA19-9, CA-125 or combinations thereof. In certain embodiments, the tumor associated marker comprises CA19-9, CA-125, CEA or combinations thereof. In certain embodiments, the tumor associated marker comprises CEA. In certain embodiments, the tumor associated marker comprises CA-125. In certain embodiments, the tumor associated marker comprises CA19-9. The levels of CA19-9, CA-125, CEA or a combination thereof can be reduced by about 10%, 20%, 25%, 30%, 35%, 40% or 50% as a result of the treatments described herein.
[0065] The h5D8 and doses of h5D8 described herein can also be used to improve other prognostic indicators of tumor / cancer burden or impact of the disease. In certain embodiments, the prognostic indicator is Eastern Cooperative Oncology Group ("ECOG") status. ECOG status is scaled from 0 to 5 as follows: 0, fully functional; able to perform daily activities as before the onset of the disease without any limitations; 1, limited physically strenuous activities but ambulatory and able to perform light and sedentary tasks. e.g. light housework, office work; 2, ambulatory and able to perform all self-care tasks but unable to perform any tasks. Spends 50% or more of the day outside of bed; 3, limited self-care. Spends 50% or more of the day in bed or chair; 4, completely immobile. Cannot perform any self-care tasks. Completely confined to bed or chair; 5, dead. In certain embodiments, the methods and doses reduce the ECOG score by 1, 2, 3, or 4. In some embodiments, the individual's ECOG status is reduced to 0, 1, 2, or 3. In some embodiments, the individual's ECOG status does not increase for at least 3, 6, 9, or 12 months. In some embodiments, the individual's ECOG status is reduced to 0 or 1 when h5D8 is administered at a dose of about 1125 or 1500 about once every other week, every 3 weeks, or every 4 weeks, including dose escalations therein. This improvement or slowing in progression may be seen after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more treatments.
[0066] In some embodiments, h5D8 treatment results in a "stable disease." In some embodiments, h5D8 and doses of h5D8 described herein result in a "stable disease" for at least 3, 6, 12, 15, 18, 24, 30, or 36 months of treatment. In some embodiments, the antibodies and doses described herein result in a "stable disease" for at least 3, 6, 12, 15, 18, 24, 30, or 36 months of treatment with h5d8 administered at a dose of about 1125 or 1500 about once every other week, every three weeks, or every four weeks, including escalations therein. In some embodiments, the antibodies and doses described herein result in a "stable disease" for at least 12 months of treatment with h5d8 administered at a dose of about 1125 or 1500 about once every other week, every three weeks, or every four weeks, including escalations therein. This delay in progression may be seen after 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more treatments.
[0067] In some embodiments, the h5D8 and doses of h5D8 described herein are useful for treating cancer or tumors. In some embodiments, h5D8 is useful for treating cancers that are refractory to at least one other treatment. In some embodiments, the treatment is chemotherapy or immunotherapy (e.g., immune checkpoint inhibitor therapy). In some embodiments, the immunotherapy is immunotherapy targeting PD-1, PDL-1, PDL-2, or any combination thereof. In some embodiments, the immunotherapy is immunotherapy targeting poliovirus receptor (PVR), TIGIT, or any combination thereof. In some embodiments, the cancer comprises breast cancer, cardiac tumor, lung cancer, small intestine cancer, colon cancer, spleen cancer, kidney cancer, bladder cancer, head cancer, neck cancer, ovarian cancer, prostate cancer, brain tumor, pancreatic cancer, skin cancer, bone tumor, bone marrow cancer, hematoma, thymus tumor, uterine cancer, testicular cancer, and liver tumor. In certain embodiments, tumors that can be treated using the antibodies of the invention include adenoma, adenocarcinoma, hemangiosarcoma, astrocytoma, epithelial carcinoma, germinoma, glioblastoma, glioma, hemangioendothelioma, hemangiosarcoma, hematoma, hepatoblastoma, leukemia, lymphoma, medulloblastoma, melanoma, neuroblastoma, osteosarcoma, retinoblastoma, rhabdomyosarcoma, sarcoma, and / or teratoma.In certain embodiments, the tumor / cancer is selected from the group consisting of acral lentiginous melanoma, actinic keratosis, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenosarcoma, adenosquamous carcinoma, astrocytic tumor, Bartholin's adenocarcinoma, basal cell carcinoma, bronchial adenocarcinoma, capillary carcinoid carcinoma, carcinosarcoma, cholangiocarcinoma, chondrosarcoma, cystadenoma, endodermal sinus tumor, endometrial atypical hyperplasia, endometrial stromal sarcoma, endometrial adenocarcinoma, ependymal tumor, swing sarcoma, focal nodular hyperplasia, gastronoma, germline tumor, glioblastoma, glucagonoma, hemangioblastoma, hemangioendothelioma, hemangioma, stem cell adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinite, intraepithelial neoplasia, squamous cell carcinoma in situ, invasive squamous cell carcinoma, large cell carcinoma, The cancer is selected from the group consisting of liposarcoma, lung carcinoma, lymphoblastic leukemia, lymphocytic leukemia, leiomyosarcoma, melanoma, malignant melanoma, malignant mesothelial tumor, nerve sheath tumor, medulloblastoma, mesothelioma, mucoepidermoid carcinoma, myeloid leukemia, neuroblastoma, neuroepithelial adenocarcinoma, nodular melanoma, osteosarcoma, ovarian carcinoma, papillary serous adenocarcinoma, pituitary tumor, plasmacytoma, pseudosarcoma, prostate carcinoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous tumor, squamous cell carcinoma, small cell carcinoma, soft tissue carcinoma, somatostatinoma, squamous cell carcinoma, squamous cell carcinoma, undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vaginal / vulvar carcinoma, VIPoma and Wilms' tumor. In certain embodiments, the tumors / cancers to be treated with one or more antibodies of the present disclosure include brain cancer, head and neck cancer, colorectal cancer, acute myeloid leukemia, pre-B cell acute lymphoblastic leukemia, bladder cancer, astrocytoma, preferably grade II, III or IV astrocytoma, glioblastoma, glioblastoma multiforme, small cell carcinoma and non-small cell carcinoma, preferably non-small cell lung carcinoma, lung adenoma, metastatic melanoma, androgen-independent metastatic prostate cancer, androgen-dependent metastatic prostate cancer, prostate adenocarcinoma and breast cancer, preferably ductal carcinoma and / or breast cancer. In certain embodiments, the cancer to be treated with the antibody of the present disclosure includes glioblastoma. In certain embodiments, the cancer to be treated with one or more antibodies of the present disclosure includes pancreatic cancer. In certain embodiments, the cancer to be treated with one or more antibodies of the present disclosure includes ovarian cancer. In certain embodiments, the cancer to be treated with one or more antibodies of the present disclosure includes lung cancer. In certain embodiments, the cancer treated with one or more antibodies of the present disclosure comprises prostate cancer, hi certain embodiments, the cancer treated with one or more antibodies of the present disclosure comprises colon cancer.In some embodiments, the cancer being treated comprises glioblastoma, pancreatic cancer, ovarian cancer, colon cancer, prostate cancer, or lung cancer. In some embodiments, the cancer is refractory to other treatments. In some embodiments, the cancer being treated is recurrent. In some embodiments, the cancer is recurrent / refractory glioblastoma, pancreatic cancer, ovarian cancer, colon cancer, prostate cancer, or lung cancer. In some embodiments, the cancer comprises advanced solid tumors, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, kidney cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma, or soft tissue cancer. In some embodiments, the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma. In some embodiments, the cancer comprises advanced solid tumors. In some embodiments, the cancer comprises appendix cancer, rectal cancer, metastatic mixed liposarcoma, and paraganglioma.
[0068] Treatment method In certain embodiments, the antibody may be administered by any suitable route for administering an antibody-containing pharmaceutical composition, such as, for example, subcutaneously, intraperitoneally, intravenously, intramuscularly, intratumorally, or intracerebrally. In certain embodiments, the antibody is administered intravenously. In certain embodiments, the antibody is administered on a suitable dosing schedule, such as, for example, once a week, twice a week, once a month, twice a month, etc. In certain embodiments, the antibody is administered about once every three weeks. The antibody may be administered in any therapeutically effective amount. In certain embodiments, a therapeutically acceptable amount is about 0.1 mg / kg to about 50 mg / kg. In certain embodiments, a therapeutically acceptable amount is about 1 mg / kg to about 40 mg / kg. In certain embodiments, a therapeutically acceptable amount is about 5 mg / kg to about 30 mg / kg. The h5D8 antibody may be administered in a fixed dose, regardless of the body weight or mass of the individual to whom the h5D8 antibody is administered. The h5D8 antibody can be administered at a fixed dose regardless of the weight or mass of the individual to whom the h5D8 antibody is administered, provided that the individual has a mass of at least about 37.5 kg. A fixed dose of about 75 mg to about 2000 mg of h5D8 can be administered. A fixed dose of about 225 mg to about 2000 mg, about 750 mg to about 2000 mg, about 1125 mg to about 2000 mg, or about 1500 mg to about 2000 mg of h5D8 can be administered. The fixed dose of h5D8 can be administered at about 75 mg. The fixed dose of h5D8 can be administered at about 225 mg. The fixed dose of h5D8 can be administered at about 750 mg. The fixed dose of h5D8 can be administered at about 1125 mg. The fixed dose of h5D8 can be administered at about 1500 mg. A fixed dose of h5D8 can be administered at approximately 2000 mg.
[0069] Other doses of h5D8 are contemplated. Fixed doses of h5D8 include about 50, 100, 150, 175, 200, 250, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1150, 1175, 1200, The compound can be administered at 1225, 1250, 1275, 1300, 1325, 1350, 1375, 1400, 1425, 1450, 1475, 1525, 1550, 1575, 1600, 1625, 1650, 1675, 1700, 1725, 1750, 1775, 1800, 1825, 1850, 1875, 1900, 1925, 1950, 1975, 2025, 2050, 2075 or 2100 mg. Any of these doses can be administered about once a week, about once every other week, about once every three weeks or about once every four weeks.
[0070] A fixed dose of about 75 mg to about 2000 mg of h5D8 can be administered about once a week. A fixed dose of about 75 mg to about 1500 mg of h5D8 can be administered about once a week. A fixed dose of about 225 mg to about 1500 mg, about 750 mg to about 1500 mg, about 1125 mg to about 1500 mg of h5D8 can be administered about once a week. A fixed dose of h5D8 can be administered about once a week at about 75 mg. A fixed dose of h5D8 can be administered about once a week at about 225 mg. A fixed dose of h5D8 can be administered about once a week at about 750 mg. A fixed dose of h5D8 can be administered about once a week at about 1125 mg. A fixed dose of h5D8 can be administered about once a week at about 1500 mg. A fixed dose of h5D8 can be administered at about 2000 mg about once per week.
[0071] A fixed dose of about 75 mg to about 2000 mg of h5D8 can be administered about once every other week. A fixed dose of about 75 mg to about 1500 mg of h5D8 can be administered about once every other week. A fixed dose of about 225 mg to about 1500 mg, about 750 mg to about 1500 mg, about 1125 mg to about 1500 mg of h5D8 can be administered about once every other week. A fixed dose of h5D8 can be administered about 75 mg about once every other week. A fixed dose of h5D8 can be administered about 225 mg about once every other week. A fixed dose of h5D8 can be administered about 750 mg about once every other week. A fixed dose of h5D8 can be administered about 1125 mg about once every other week. A fixed dose of h5D8 can be administered at about 1500 mg about once every other week. A fixed dose of h5D8 can be administered at about 2000 mg about once every other week.
[0072] A fixed dose of about 75 mg to about 2000 mg of h5D8 can be administered about once every three weeks. A fixed dose of about 75 mg to about 1500 mg of h5D8 can be administered about once every three weeks. A fixed dose of about 225 mg to about 1500 mg, about 750 mg to about 1500 mg, about 1125 mg to about 1500 mg of h5D8 can be administered about once every three weeks. A fixed dose of h5D8 can be administered at about 75 mg about once every three weeks. A fixed dose of h5D8 can be administered at about 225 mg about once every three weeks. A fixed dose of h5D8 can be administered at about 750 mg about once every three weeks. A fixed dose of h5D8 can be administered at about 1125 mg about once every three weeks. A fixed dose of h5D8 can be administered at about 1500 mg about once every three weeks. A fixed dose of h5D8 can be administered at about 2000 mg about once every three weeks.
[0073] A fixed dose of about 75 mg to about 2000 mg of h5D8 can be administered about once every 4 weeks. A fixed dose of about 75 mg to about 1500 mg of h5D8 can be administered about once every 4 weeks. A fixed dose of about 225 mg to about 1500 mg, about 750 mg to about 1500 mg, about 1125 mg to about 1500 mg of h5D8 can be administered about once every 4 weeks. A fixed dose of h5D8 can be administered at about 75 mg about once every 4 weeks. A fixed dose of h5D8 can be administered at about 225 mg about once every 4 weeks. A fixed dose of h5D8 can be administered at about 750 mg about once every 4 weeks. A fixed dose of h5D8 can be administered at about 1125 mg about once every 4 weeks. A fixed dose of h5D8 can be administered at about 1500 mg about once every four weeks. A fixed dose of h5D8 can be administered at about 2000 mg about once every four weeks.
[0074] The h5D8 antibody may be administered at a dose based on the body weight or mass of the individual to whom the h5D8 antibody is administered. A body weight adjusted dose of about 1 mg / kg to about 25 mg / kg of h5D8 may be administered. A body weight adjusted dose of about 3 mg / kg to about 25 mg / kg, about 10 mg / kg to about 25 mg / kg, about 15 mg / kg to about 25 mg / kg, or about 20 mg / kg to about 25 mg / kg of h5D8 may be administered. The body weight adjusted dose of h5D8 may be administered at about 1 mg / kg. The body weight adjusted dose of h5D8 may be administered at about 3 mg / kg. The body weight adjusted dose of h5D8 may be administered at about 10 mg / kg. The body weight adjusted dose of h5D8 may be administered at about 15 mg / kg. The body weight adjusted dose of h5D8 may be administered at about 20 mg / kg. The body weight adjusted dose of h5D8 may be administered at about 25 mg / kg.
[0075] A weight-adjusted dose of about 1 mg / kg to about 25 mg / kg of h5D8 can be administered about once every three weeks. A weight-adjusted dose of about 3 mg / kg to about 25 mg / kg, about 10 mg / kg to about 20 mg / kg, about 15 mg / kg to about 25 mg / kg, or about 20 mg / kg to about 25 mg / kg of h5D8 can be administered about once every week, every other week, every three weeks, or every four weeks.
[0076] Other weight-adjusted doses of h5D8 are contemplated. Weight-adjusted doses of h5D8 can be administered at about 2 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, 21 mg / kg, 22 mg / kg, 23 mg / kg, 24 mg / kg, 26 mg / kg, 27 mg / kg, 28 mg / kg, 29 mg / kg, or 30 mg / kg. Any of these doses can be administered once a week, about once every other week, about once every three weeks, or about once every four weeks.
[0077] A weight adjusted dose of h5D8 can be administered at about 1 mg / kg once a week. A weight adjusted dose of h5D8 can be administered at about 3 mg / kg once a week. A weight adjusted dose of h5D8 can be administered at about 10 mg / kg once a week. A weight adjusted dose of h5D8 can be administered at about 15 mg / kg once a week. A weight adjusted dose of h5D8 can be administered at about 20 mg / kg once a week. A weight adjusted dose of h5D8 can be administered at about 25 mg / kg once a week.
[0078] A weight adjusted dose of h5D8 can be administered at about 1 mg / kg about once every other week. A weight adjusted dose of h5D8 can be administered at about 3 mg / kg about once every other week. A weight adjusted dose of h5D8 can be administered at about 10 mg / kg about once every other week. A weight adjusted dose of h5D8 can be administered at about 15 mg / kg about once every other week. A weight adjusted dose of h5D8 can be administered at about 20 mg / kg about once every other week. A weight adjusted dose of h5D8 can be administered at about 25 mg / kg about once every other week.
[0079] A weight adjusted dose of h5D8 can be administered at about 1 mg / kg about once every three weeks. A weight adjusted dose of h5D8 can be administered at about 3 mg / kg about once every three weeks. A weight adjusted dose of h5D8 can be administered at about 10 mg / kg about once every three weeks. A weight adjusted dose of h5D8 can be administered at about 15 mg / kg about once every three weeks. A weight adjusted dose of h5D8 can be administered at about 20 mg / kg about once every three weeks. A weight adjusted dose of h5D8 can be administered at about 25 mg / kg about once every three weeks.
[0080] A weight adjusted dose of h5D8 can be administered at about 1 mg / kg about once every 4 weeks. A weight adjusted dose of h5D8 can be administered at about 3 mg / kg about once every 4 weeks. A weight adjusted dose of h5D8 can be administered at about 10 mg / kg about once every 4 weeks. A weight adjusted dose of h5D8 can be administered at about 15 mg / kg about once every 4 weeks. A weight adjusted dose of h5D8 can be administered at about 20 mg / kg about once every 4 weeks. A weight adjusted dose of h5D8 can be administered at about 25 mg / kg about once every 4 weeks.
[0081] Any of the doses described herein can be administered iv over a period of at least about 60 minutes; however, this period can vary to some extent based on the conditions appropriate for each individual administration.
[0082] The doses described herein can result in a serum / plasma half-life of h5D8 of about 15 to about 20 days. In certain embodiments, the doses result in a serum half-life of about 16 to 19 days. In certain embodiments, the doses result in a serum half-life of about 17 to 18 days. In certain embodiments, doses of h5D8 administered at 750 mg, 1125 mg, or 1500 mg result in a serum half-life of about 17 or 18 days.
[0083] Any of the doses described herein can be prepared as a composition for treating the cancers / tumors described herein.
[0084] Pharmaceutically acceptable excipients, carriers and diluents In certain embodiments, the antibodies of the present disclosure are administered suspended in a sterile solution. In certain embodiments, the solution comprises a physiologically suitable salt concentration (e.g., NaCl). In certain embodiments, the solution comprises about 0.6%-1.2% NaCl. In certain embodiments, the solution comprises about 0.7%-1.1% NaCl. In certain embodiments, the solution comprises about 0.8%-1.0% NaCl. In certain embodiments, a highly concentrated stock solution of the antibody can be diluted in about 0.9% NaCl. In certain embodiments, the solution comprises about 0.9% NaCl. In certain embodiments, the solution further comprises one or more of the following: a buffer, such as acetate, citrate, histidine, succinate, phosphate, bicarbonate, and hydroxymethylaminomethane (Tris); a surfactant, such as polysorbate 80 (Tween 80), polysorbate 20 (Tween 20), polysorbate, and poloxamer 188; a polyol / disaccharide / polysaccharide, such as glucose, dextrose, mannose, mannitol, sorbitol, sucrose, trehalose, and dextran 40; an amino acid, such as histidine, glycine, or arginine; an antioxidant, such as ascorbic acid, methionine; and a chelating agent, such as EGTA or EGTA. In certain embodiments, the antibodies of the present disclosure are transported / stored lyophilized and reconstituted prior to administration. In certain embodiments, the lyophilized antibody formulation includes a bulking agent such as mannitol, sorbitol, sucrose, trehalose, and dextran 40. In certain embodiments, the anti-LIF antibody of the present disclosure can be transported and stored as a concentrated stock solution to be diluted at the point of useful treatment. In certain embodiments, the stock solution includes about 25 mM histidine, about 6% sucrose, about 0.01% polysorbate, and about 20 mg / mL of anti-LIF antibody. In certain embodiments, the pH of the solution is about 6.0. In certain embodiments, the form administered to an individual is an aqueous solution including about 25 mM histidine, about 6% sucrose, about 0.01% polysorbate 80, and about 20 mg / mL of h5D8 antibody. In certain embodiments, the pH of the solution is about 6.0.
[0085] The h5D8 antibody described herein can be included in a kit that includes a vial filled with a sterile solution comprising h5D8 antibody at a concentration of about 20 mg / mL, about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80. The vial can be a disposable glass vial. The disposable glass vial can be filled with about 10 mL of h5D8 antibody at a concentration of about 20 mg / mL, about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80. In certain embodiments, the pH of the solution is about 6.0. The h5D8 antibody described herein can be included in a kit that includes a vial filled with a lyophilized composition comprising h5D8 antibody, which when reconstituted in an appropriate amount of sterile diluent yields a concentration of about 20 mg / mL of h5D8 antibody, about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80. The vial can be a disposable glass vial.
[0086] The antibodies described herein can be administered or prepared or diluted for administration in a variety of ways depending on the dose level to be ultimately delivered to the patient. This can be done, for example, to reduce particulate matter, for example, to optimize the pharmaceutical properties of the patient dose. h5D8 can be prepared at a concentration of about 8 mg / mL, regardless of the final dose delivered to the patient. In certain embodiments, h5D8 can be prepared at a level of about 10, 9, 8, 7, 6, 5, or 4 mg / mL or less. In certain embodiments, h5D8 can be prepared at a level of about 1, 2, 3, 4, 5, 6, or more than 7 mg / mL. EXAMPLES
[0087] The following illustrative examples are representative of embodiments of the compositions and methods described herein, but are not intended to be limiting in any way.
[0088] Example 1 - Generation of rat antibodies specific for LIF A cDNA encoding amino acids 23-202 of human LIF was cloned into an expression plasmid (Aldevron GmbH, Freiburg, Germany). Groups of laboratory rats (Wistar strain) were immunized by intradermal application of DNA-coated gold particles using a handheld device for microparticle bombardment ("gene gun"). Cell surface expression on transiently transfected HEK cells was confirmed using an anti-tag antibody that recognizes the tag added to the N-terminus of the LIF protein. Serum samples were collected after a series of immunizations and tested by flow cytometry on HEK cells transiently transfected with the expression plasmid described above. Antibody-producing cells were isolated and fused with mouse myeloma cells (Ag8) according to standard procedures. Hybridoma-producing antibodies specific for LIF were identified by screening in a flow cytometry assay as described above. The cell pellets of the positive hybridoma cells were prepared using an RNA protection agent (RNAlater, product number: AM7020, ThermoFisher Scientific) and further processed for sequencing the variable domains of the antibodies.
[0089] Example 2 - Generation of mouse antibodies specific for LIF A cDNA encoding amino acids 23-202 of human LIF was cloned into an expression plasmid (Aldevron GmbH, Freiburg, Germany). Groups of laboratory mice (NMRI strain) were immunized by intradermal application of DNA-coated gold particles using a handheld device for microparticle bombardment ("gene gun"). Cell surface expression on transiently transfected HEK cells was confirmed using an anti-tag antibody that recognizes the tag added to the N-terminus of the LIF protein. Serum samples were collected after a series of immunizations and tested by flow cytometry on HEK cells transiently transfected with the expression plasmid described above. Antibody-producing cells were isolated and fused with mouse myeloma cells (Ag8) according to standard procedures. Hybridoma-producing antibodies specific for LIF were identified by screening in a flow cytometry assay as described above. The cell pellets of the positive hybridoma cells were prepared using an RNA protection agent (RNAlater, product number: AM7020, ThermoFisher Scientific) and further processed for sequencing the variable domains of the antibodies.
[0090] Example 3 - Humanization of a rat antibody specific for LIF One clone (5D8) from rat immunization was selected for subsequent humanization. Humanization was performed using standard CDR grafting methods. Heavy and light chain regions were cloned from the 5D8 hybridoma using standard molecular cloning techniques and sequenced by the Sanger method. BLAST searches were then performed against human heavy and light chain variable sequences, and four sequences from each were selected as receptor frameworks for humanization. These receptor frameworks were deimmunized to remove T cell response epitopes. The heavy and light chain CDR1, CDR2, and CDR3 of 5D8 were cloned into four different heavy chain receptor frameworks (H1-H4) and four different light chain frameworks (L1-L4). All 16 antibodies were then tested for: expression in CHO-S cells (Selexis); inhibition of LIF-induced STAT3 phosphorylation; and binding affinity by surface plasmon resonance (SPR). These experiments are summarized in Table 1.
[0091] [Table 1]
[0092] After 10 days of cell culture, the expression performance of the transfected cells was evaluated in Erlenmeyer flasks (3 × 10 cells) in fed-batch culture. 5 Cells were compared in culture volume: 200 mL, seeded at 1000 cells / mL. At this time point, cells were harvested and secreted antibodies were purified using a Protein A column and subsequently quantified. All humanized antibodies were expressed except for those that used the H3 heavy chain. The H2 and L2 variable regions performed well compared to the other variable regions (SEQ ID NO: 42 and SEQ ID NO: 46).
[0093] Inhibition of LIF-induced STAT3 phosphorylation at tyrosine 705 was determined by Western blot. U251 glioma cells were plated at a density of 100,000 cells / well in 6-well plates. Cells were cultured in complete medium for 24 h before any treatment, after which cells were serum starved for 8 h. Cells were then incubated overnight with the indicated antibodies at a concentration of 10 μg / ml. After treatment, proteins were obtained in radioimmunoprecipitation assay (RIPA) lysis buffer containing phosphate and protease inhibitors, quantified (BCA protein assay, Thermo Fisher Scientific), and used in Western blots. For Western blots, membranes were blocked in 5% skim milk-TBST for 1 h and incubated with primary antibodies overnight (p-STAT3, Product No. 9145, Cell Signaling or STAT3, Product No. 9132, Cell Signaling) or for 30 min (β-actin-peroxidase, Product No. A3854, Sigma-Aldrich). Membranes were then washed with TBST, incubated with secondary antibodies, and washed again. Proteins were detected by chemiluminescence (SuperSignal Substrate, Product No. 34076, Thermo Fisher Scientific). The results are shown in Figure 1. The darker the pSTAT3 band, the less inhibition was present. In labeled 5D8 (non-humanized rat), lanes A (H0L0), C (H1L2), D (H1L3) and G (H2L2), inhibition was high; in lanes H (H2L3), O (H4L2) and P (H4L3), inhibition was moderate; in lanes B (H1L1), E (H1L4), F (H2L1), I (H2L4), N (H4L1) and Q (H4L4), inhibition was absent.
[0094] Antibodies that showed inhibition of LIF-induced STAT3 phosphorylation were then analyzed by SPR to determine binding affinity. Briefly, a Biacore™ 2002 Instrument was used to monitor the binding of amine-linked hLIF to A (H0L0), C (H1L2), D (H1L3) and G (H2L2), H (H2L3) and O (H4L2) humanized antibodies. The kinetic constants and affinities were determined by mathematical sensorgram fitting (Langmuir interaction model [A+B=AB]) of all sensorgrams generated on all sensor chip surfaces at six ligand concentrations. To calculate the kinetic constants and affinities, the best fitted curves (minimum χ 2 ) was used. See Table 1.
[0095] Since bivalent antibodies were used as analytes in this experimental setup, the best-fit sensorgrams were also analyzed based on the bivalent analyte approximation model [A+B=AB; AB+B=AB2] to gain more insight into the target binding mechanism of the humanized antibodies. Kinetic sensorgram analysis using the bivalent approximation model [A+B=AB; AB+B=AB2] confirmed the relative affinity ranking of the mAb samples.
[0096] For more detailed analysis, humanized 5D8 containing H2 and L2 was selected due to its high binding affinity and high yield from batch cultures.
[0097] Example 4 - Humanization of clone 5D8 improves binding to LIF We selected the H2L2 clone (h5D8) for further analysis and compared it by SPR for binding to the parental rat 5D8 (r5D8) and the mouse clone 1B2. The 1B2 antibody is a previously disclosed mouse anti-LIF antibody (DSM ACC3054) previously deposited at the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH and was included for comparative purposes. Recombinant human LIF purified from E. coli and HEK-293 cells, respectively, was used as ligand. LIF from human or E. coli sources was covalently coupled to the surface of a Biacore optical sensor chip using amine coupling chemistry and binding affinities were calculated from the rate constants.
[0098] Materials and Methods Human LIF from E. coli was obtained from Millipore; reference LIF 1010; human LIF from HEK-293 cells was obtained from ACRO Biosystems; reference LIF-H521b. LIF was coupled to the sensor chip using the Biacore Amine Binding Kit (BR-1000-50; GE-Healthcare, Uppsala). Samples were run on a Biacore™ 2002 Instrument using a CM5 optical sensor chip (BR-1000-12; GE-Healthcare, Uppsala). Biacore HBS-EP buffer was used during the run of the machine (BR-1001-88; GE-Healthcare, Uppsala). Kinetic analysis of the binding sensorgrams was performed using BIAevaluation 4.1 software. The rate constants and affinities were determined by mathematical sensorgram fitting (Langmuir interaction model [A+B=AB]) of all sensorgrams generated on the entire sensor chip surface with increasing analyte concentration. The sensorgrams were further subjected to a bivalent analyte sensorgram fitting model [A+B=AB; AB+B=AB], including a contribution analysis, to generate estimates based on bivalent contributions to the determined Langmuir antibody-target affinity (e.g., avidity contributions). 2The best fitted curve for each concentration (minimum χ 2 ) was used to calculate kinetic constants and affinities. A summary of these affinity experiments is shown in Table 2 (human LIF produced in E. coli) and Table 3 (human LIF produced in HEK 293 cells).
[0099] [Table 2]
[0100] [Table 3]
[0101] Langmuir 1:1 sensorgram fitting models from this set of experiments indicate that the humanized 5D8 (h5D8) antibody bound with approximately 10-25 fold higher affinity to human LIF than murine 1B2 and r5D8.
[0102] The h5D8 antibody was then tested by SPR against LIF from multiple species. h5D8 SPR binding kinetics were performed against recombinant LIF samples from a variety of species and expression systems: human LIF (E. coli, HEK293 cells); mouse LIF (E. coli, CHO cells); rat LIF (E. coli); and cynomolgus LIF (yeast, HEK293 cells).
[0103] Materials and Methods The h5D8 antibody was immobilized on the sensor chip surface by non-covalent Fc-specific capture. Recombinant Ig (Fc)-specific S. aureus protein A / G was used as a capture agent that allows a spatially uniform and flexible presentation of anti-LIF antibodies to the LIF samples. The sources of the LIF samples were as follows: human LIF (from E. coli; Millipore reference number LIF 1050); human LIF (from HEK cells, ACRO Biosystems LIF-H521); mouse LIF (from E. coli; Millipore product number NF-LIF2010); mouse LIF (from CHO cells; Reprokine product number RCP09056); monkey LIF (yeast, Kingfisher Biotech product number RP1074Y); monkey LIF produced in HEK-293 cells. Total h5D8 showed binding to LIF from several species. A summary of the affinity experiments is shown in Table 4.
[0104] [Table 4]
[0105] Example 5 - Humanized clone 5D8 inhibits LIF-induced phosphorylation of STAT3 in vitro To determine the biological activity of h5D8, the humanized and parental versions were tested in a cell culture model of LIF activation. Figure 2A shows that the humanized clones show increased inhibition of STAT3 phosphorylation (Tyr 705) when glioma cell lines are incubated with human LIF. Figure 2B shows an experiment using the same setup of Figure 2A repeated with different dilutions of h5D8 antibody.
[0106] method U251 glioma cells were plated in 6-well plates at a density of 150,000 cells / well. Cells were cultured in complete medium for 24 hours before any treatment. Cells were then treated overnight with r5D8 or h5D8 anti-LIF antibodies at a concentration of 10 μg / ml or were not treated (control cells).
[0107] After treatment, proteins were obtained in radioimmunoprecipitation assay (RIPA) lysis buffer containing phosphate and protease inhibitors, quantified (BCA protein assay, Thermo Fisher Scientific), and used in Western blots. For Western blots, membranes were blocked in 5% skim milk-TBST for 1 hour and incubated with primary antibodies overnight (p-STAT3, Product No. 9145, Cell Signaling or STAT3, Product No. 9132, Cell Signaling) or for 30 minutes (β-actin-peroxidase, Product No. A3854, Sigma-Aldrich). Membranes were then washed with TBST, incubated with secondary antibodies if necessary, and washed again. Proteins were detected by chemiluminescence (SuperSignal Substrate, Product No. 34076, Thermo Fisher Scientific).
[0108] Example 6 - IC of h5D8 antibody treatment on endogenous levels of LIF in U-251 cells 50 value Applicants further demonstrated a very low IC of 490 pmol (Figure 3A) for biological inhibition of h5D8 under serum-starved conditions in U-251 cells. 50 was determined. See Figures 3A and 3B and Table 5 for representative results.
[0109] [Table 5]
[0110] method U-251 cells were seeded at 600,000 cells per 6 cm plate (depending on condition). Cells were treated with h5D8 at the corresponding concentrations (titration) overnight at 37°C under serum starvation (0.1% FBS). As a positive control for pSTAT3, recombinant LIF (R&D number: 7734-LF / CF) was used to stimulate cells at 1.79 nM for 10 min at 37°C. As a negative control for pSTAT3, JAK I inhibitor (Calbiochem number 420099) was used at 1 μM for 30 min at 37°C. Cells were then harvested on ice for lysis according to the Meso Scale Discovery Multi-Spot Assay System Total STAT3 (Product number: K150SND-2) and Phospho-STAT3 (Tyr705) (Product number: K150SVD-2) kit protocols to measure protein levels detectable by MSD Meso Sector S600.
[0111] Example 7 - Additional antibodies that specifically bind to human LIF Other rat antibody clones (10G7 and 6B5) that specifically bind to human LIF were identified and a summary of their binding characteristics is shown in Table 6 below, with clone 1B2 serving as a comparison.
[0112] method Kinetic real-time binding assays were performed with recombinant LIF target proteins [human LIF (E. coli); Millipore product number: LIF 1010 and human LIF (HEK293 cells); ACRO Biosystems product number: LIF-H521b] as analytes and anti-LIF mAbs 1B2, 10G7 and 6B5 immobilized on the surface of a CM5 optical sensor chip.
[0113] The kinetic constants and affinities were obtained by mathematical sensorgram fitting using a Langmuir 1:1 binding model applying global (simultaneous fitting of a set of sensorgrams) and single curve fitting algorithms. The adequacy of the global fit was evaluated using the k obs was assessed by analysis.
[0114] [Table 6]
[0115] Example 8 - Additional anti-LIF antibodies inhibit LIF-induced phosphorylation of STAT3 in vitro Additional clones were tested for their ability to inhibit LIF-induced phosphorylation of STAT3 in cell culture. As shown in FIG. 4, clone 10G7 and previously detailed r5D8 showed a high inhibition of LIF-induced STAT3 phosphorylation compared to clone 1B2. Anti-LIF polyclonal antiserum (positive) was included as a positive control. 6B5 showed no inhibition, which can be explained by a possible lack of 6B5 binding to the non-glycosylated LIF used in this experiment.
[0116] method Patient-derived glioma cells were plated at a density of 150,000 cells / well in 6-well plates. Cells were cultured in GBM medium consisting of Neurobasal medium (Life Technologies) supplemented with B27 (Life Technologies), penicillin / streptomycin, and growth factors (20 ng / ml EGF and 20 ng / ml FGF-2 [PeproTech]) for 24 hours before any treatment. The following day, cells were treated or not with recombinant LIF produced in Escherichia coli (E. coli) or a mixture of recombinant LIF plus the indicated antibodies (final concentrations of 10 μg / ml for antibodies and 20 ng / ml for recombinant LIF) for 15 minutes. After treatment, proteins were obtained in radioimmunoprecipitation assay (RIPA) lysis buffer containing phosphate and protease inhibitors, quantified (BCA protein assay, Thermo Fisher Scientific), and used in Western blots. For Western blots, membranes were blocked in 5% skim milk-TBST for 1 h and incubated with primary antibodies overnight (p-STAT3, Product No. 9145, Cell Signaling) or for 30 min (β-actin-peroxidase, Product No. A3854, Sigma-Aldrich). Membranes were then washed with TBST, incubated with secondary antibodies if necessary, and washed again. Proteins were detected by chemiluminescence (SuperSignal Substrate, Product No. 34076, Thermo Fisher Scientific).
[0117] Example 9 - LIF is highly overexpressed across multiple tumor types To determine the extent of LIF expression, immunohistochemical studies were performed on multiple human tumor types. As shown in Figure 5, LIF is highly expressed in glioblastoma multiforme (GBM), non-small cell lung cancer (NSCLC), ovarian cancer, and colorectal cancer (CRC).
[0118] Example 10 - Humanized clone h5D8 inhibits tumor growth in a mouse model of non-small cell lung cancer To determine the ability of the humanized 5D8 clone to inhibit LIF-positive cancer in vivo, the antibody was tested in a mouse model of non-small cell lung cancer (NSCLC). Figure 6 shows the reduction in tumor growth in mice treated with the antibody compared to the vehicle negative control.
[0119] method The murine non-small cell lung cancer (NSCLC) cell line KLN205, which contains high LIF levels, was stably infected with a lentivirus expressing the firefly luciferase gene for in vivo chemiluminescence monitoring. To develop the mouse model, 5 × 10 5 KLN205 non-small cell lung cancer (NSCLC) cells were orthotopically implanted into the left lung of 8-week-old immunocompetent syngeneic DBA / 2 mice by intercostal puncture. Mice received either control vehicle or 15 mg / kg or 30 mg / kg h5D8 antibody intraperitoneally twice weekly, and tumor growth was monitored by chemiluminescence. For chemiluminescence imaging, mice received an intraperitoneal injection of 0.2 mL of 15 mg / mL D-luciferin anesthesia under 1–2% inhaled isoflurane anesthesia. Chemiluminescence signals were monitored using an IVIS system 2000 series (Xenogen Corp., Alameda, CA, USA) consisting of a highly sensitive cooled CCD camera. Living Image software (Xenogen Corp.) was used to add a grid to the image data and integrate the total chemiluminescence signal within each framed region. Data were analyzed using the total photon flux emission (photons / sec) within the region of interest (ROI). The results demonstrate that treatment with h5D8 antibody promotes tumor regression. Data are presented as mean ± SEM.
[0120] Example 11 - h5D8 inhibits tumor growth in a mouse model of glioblastoma multiforme In an orthotopic GBM tumor model using the luciferase expressing human cell line U251, r5D8 significantly reduced tumor volume in mice administered 300 μg of r5D8 and h5D8 by intraperitoneal (IP) injection twice weekly. The results of this study are shown in FIG. 7A (quantification at day 26 post-treatment). This experiment was further carried out using humanized h5D8 mice treated with 200 μg or 300 μg and showed a statistically significant reduction in tumors 7 days after treatment.
[0121] method U251 cells stably expressing luciferase were harvested, washed in PBS, centrifuged at 400g for 5 min, resuspended in PBS, and counted using an automated cell counter (Countess, Invitrogen). Cells were kept on ice to maintain maximum viability. Mice were anesthetized with intraperitoneal administration of ketamine (Ketolar50®) / xylase (Rompun®) (75 mg / kg and 10 mg / kg, respectively). Each mouse was carefully placed in a stereotaxic apparatus and immobilized. Head hair was removed using depilatory cream, and the scalp was incised using a scalpel to expose the skull. A small incision was carefully made with a drill at the coordinates 1.8 mm lateral and 1 mm anterior to lambda. 5 μL of cells were inoculated into the right striatum at a depth of 2.5 mm using a Hamilton 30G syringe. The head incision was closed with Hystoacryl tissue adhesive (Braun) and the mice were injected with the subcutaneous analgesic meloxicam (Metacam®) (1 mg / kg). The final number of cells implanted in each mouse was 3 × 10 5 There were 100 pieces.
[0122] Mice were treated with h5D8 administered intraperitoneally twice weekly. Treatment began immediately after tumor cell inoculation on day 0. Mice received a total of two doses of h5D8 or vehicle control.
[0123] Body weight and tumor volume: Body weight was measured twice weekly and tumor growth was quantified by chemiluminescence (Xenogen IVIS Spectrum) on day 7. To quantify chemiluminescence activity in vivo, mice were anesthetized with isofluorane and injected intraperitoneally with luciferin substrate (PerkinElmer) (167 μg / kg).
[0124] Tumor size, determined by bioluminescence (Xenogen IVIS Spectrum), was assessed on day 7. Individual tumor measurements and means ± SEM for each treatment group were calculated. Statistical significance was determined using the unpaired, nonparametric Mann-Whitney U test.
[0125] Example 12 - h5D8 inhibits tumor growth in a mouse model of ovarian cancer The efficacy of r5D8 was evaluated in two other syngeneic tumor models. IP administration of 300 μg of r5D8 twice weekly in the ovarian orthotopic tumor model ID8 significantly inhibited tumor growth as measured by abdominal volume (FIGS. 8A and 8B). The results in FIG. 8C show that h5D8 also reduced tumor volume at doses above 200 μg.
[0126] method ID8 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen), 40 U / mL penicillin and 40 μg / mL streptomycin (PenStrep) (Gibco, Invitrogen), and 0.25 μg / mL Plasmocin (Invivogen).
[0127] ID8 cells were harvested, washed in PBS, centrifuged at 400g for 5 min, and resuspended in PBS. Cells were kept on ice to maintain maximum viability, and 200 μL of cell suspension was injected intraperitoneally using a 27G needle. The final cell number implanted in mice was 5 × 10 6 There were 100 pieces.
[0128] Mice were treated with twice weekly doses of h5D8 administered intraperitoneally at various doses as indicated. Body weight was measured twice weekly and tumor progression was monitored by measuring abdominal circumference using calipers (Fisher Scientific).
[0129] Example 13 - r5D8 inhibits tumor growth in a mouse model of colorectal cancer In mice bearing subcutaneous colon CT26 tumors, r5D8 (300 μg IP administered twice weekly) significantly inhibited tumor growth (FIGS. 9A and 9B).
[0130] method CT26 cells were cultured in Roswell Park Memorial Institute medium (RPMI [Gibco, Invitrogen]) supplemented with 10% fetal bovine serum (FBS), 40 U / mL penicillin and 40 μg / mL streptomycin (PenStrep), and 0.25 μg / mL Plasmocin.
[0131] CT26 cells (8 x 10 5 100 μL of CT26 cells were trypsinized, rinsed with PBS, centrifuged at 400 g for 5 min, and resuspended in 100 μL of PBS. Cells were kept on ice to avoid cell death. CT26 cells were administered to mice by subcutaneous injection using a 27 G needle.
[0132] 300 μg of r5D8 or vehicle control was administered to mice via intraperitoneal administration (IP) twice weekly starting on day 3 after CT26 cell implantation.
[0133] Body weights and tumor volumes were measured three times a week. Tumor volumes were measured using calipers (Fisher Scientific).
[0134] Example 14 - r5D8 reduces inflammatory infiltration in tumor models In the U251 GBM orthotopic model, expression of CCL22, a marker of M2 polarized macrophages, was significantly decreased in tumors treated with r5D8, as shown in Figure 10A. This finding was further corroborated in a physiologically relevant organotypic tissue slice culture model using r5D8, where three patient samples showed significant decreases in expression of CCL22 and CD206 (MRC1), also a marker of M2 macrophages, after treatment, as shown in Figure 10B (compare control, top, with treated, bottom, for both MRC1 and CCL22). Furthermore, r5D8 reduced CCL22 expression in syngeneic ID8 (Figure 10C) and CT26 (Figure 10D) tumors in immune-competent mice. + M2 macrophages were also reduced.
[0135] Example 15 - r5D8 Increases Non-Myeloid Effector Cells To explore further immune mechanisms, the effect of r5D8 on T cells and other non-myeloid effector cells within the tumor microenvironment was evaluated. In the ovarian orthotopic ID8 syngeneic model, r5D8 treatment increased intratumoral NK cells and total and activated CD4+ cells, as shown in Figure 11A. + and CD8 + Similarly, in a syngeneic colon CT26 tumor model, r5D8 increased intratumoral NK cells, increased CD4+ and CD8+ T cells, and increased CD4 + CD25 + FoxP3 + There was a tendency to decrease T-reg cells. + CD25 + FoxP3 + A trend towards a decrease in T-reg cells was also observed in the syngeneic orthotopic KLN205 tumor model following r5D8 treatment, as shown in Figure 11C. Consistent with the recruitment of T cells to mediate efficacy, CD4 + and CD8 + Depletion of T cells inhibited the antitumor efficacy of r5D8, as shown in FIG.
[0136] Methods for deleting T cells CT26 cells were cultured in RPMI culture medium (Gibco, Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen), 40 U / mL penicillin and 40 μg / mL streptomycin (PenStrep) (Gibco, Invitrogen), and 0.25 μg / mL Plasmocin (Invivogen). CT26 cells (5 × 10 5 ) were harvested, rinsed with PBS, centrifuged at 400g for 5 min, and resuspended in 100 μL of PBS. Cells were kept on ice to avoid cell death. CT26 cells were administered to the left and right flanks of mice by subcutaneous injection using a 27G syringe. Mice were treated twice weekly with r5D8 administered intraperitoneally as indicated in the study design. Vehicle control (PBS), rat r5D8 and / or anti-CD4 and anti-CD8 were administered to mice twice weekly by intraperitoneal injection (IP) as described in the study design. All antibody treatments were administered simultaneously.
[0137] Example 16 - Crystal structure of h5D8 in complex with human LIF The crystal structure of h5D8 was resolved to 3.1 Å resolution to determine the epitope on LIF bound by h5D8 and to determine the residues of h5D8 that precipitate upon binding. The co-crystal structure revealed that the N-terminal loop of LIF is centrally located between the light and heavy chain variable regions of h5D8 (FIG. 13A). Furthermore, h5D8 interacts with residues on helices A and C of LIF, thereby forming a conformational epitope that is discontinuous. Binding is driven by several salt bridges, H-bonds, and van der Waals interactions (Table 7, FIG. 13B). The h5D8 epitope on LIF spans the region of interaction with gp130. See Boulanger, MJ, Bankovich, AJ, Kortemme, T., Baker, D. & Garcia, KC Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Molecular cell 12, 577-589 (2003). The results are summarized in Table 7 below and depicted in Figure 13.
[0138] [Table 7]
[0139] [Table 8]
[0140] method LIF was generated from HEK 293S (Gnt I - / -() cells and purified using Ni-NTA affinity chromatography followed by gel filtration chromatography using 20 mM Tris (pH 8.0) and 150 mM NaCl. Recombinant h5D8 Fab was transiently expressed in HEK 293F cells and purified using KappaSelect affinity chromatography followed by cation exchange chromatography. Purified h5D8 Fab and LIF were mixed in a 1:2.5 molar ratio and incubated at room temperature for 30 minutes, followed by deglycosylation using EndoH. The complex was subsequently purified using gel filtration chromatography. The complex was concentrated to 20 mg / mL and set up for crystallization trials using a sparse matrix screen. Crystals were formed at 4 °C under conditions containing 19 (v / v)% isopropanol, 19 (w / v)% PEG 4000, 5 (v / v)% glycerol, 0.095 M sodium citrate (pH 5.6). Crystals were resolved to 3.1 Å resolution at the 08ID-1 beamline at the Canadian Light Source (CLS). Data were collected, processed and scaled using XDS by Kabsch et al.Xds.Acta crystallographica.Section D,Biological crystallography 66,125-132 (2010). The structure was determined by molecular replacement using Phaser as per McCoy et al.Phaser crystallographic software.J Appl Crystallogr 40,658-674 (2007). The structure was analyzed using the acceptable R work and R freeSeveral iterations of model building and refinement were performed using Coot and phenix.refine until convergence to . See Emsley et al. Features and development of Coot. Acta crystallographica. Section D, Biological crystallography 66, 486-501 (2010); and Adams, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta crystallographica. Section D, Biological crystallography 66, 213-221 (2010), respectively. Figures were generated in PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schroedinger, LLC).
[0141] Example 17 - h5D8 has a high degree of specificity for LIF. We wished to test the binding of h5D8 to other LIF family members to determine binding specificity. Using Octet96 analysis, binding of h5D8 to human LIF is approximately 100-fold higher than that of LIF's highest homologous IL-6 family member, Oncostatin M (OSM), when both proteins are produced in E. coli. h5D8 shows no binding to OSM when both proteins are produced in mammalian systems. The data are summarized in Table 8.
[0142] [Table 9]
[0143] method Octet binding experiments: Reagents were used and prepared according to the manual provided by the manufacturer. Basic kinetic experiments were performed using Octet Data Acquisition software version 9.0.0.26 as follows: Sensor / program setup: i) equilibration (60 sec); ii) loading (15 sec); iii) baseline (60 sec); iv) association (180 sec); and v) dissociation (600 sec).
[0144] Octet affinity of h5D8 for cytokines: Basic kinetic experiments were performed using Octet data acquisition software version 9.0.0.26 as follows: Amine-reactive second generation biosensors (AR2G) were hydrated in water for at least 15 min. Amine-coupled coupling of h5D8 to the biosensor was performed using the Amine Coupling Second Generation kit according to ForteBio Technical Note 26 (see references). The soaking steps were: i) equilibration in water for 60 seconds; ii) activation in 20 mM ECD, 10 mM sulfo-NHS in water for 300 seconds; iii) immobilization in 10 mM sodium acetate, pH 6.0, 10 μg / ml h5D8 for 600 seconds; iv) quenching in 1 M ethanolamine, pH 8.5 for 300 seconds; v) baseline in water for 120 seconds, then kinetic experiments were performed using subsequent soaking and release at 30° C. and 1000 rpm. The following regeneration / neutralization cycles were performed at 30° C., 1000 rpm: vi) baseline for 60 sec in 1× kinetics buffer; vii) association of appropriate serial dilutions of cytokines for 180 sec in 1× kinetics buffer; viii) dissociation for 300 sec in 1× kinetics buffer; ix) three regeneration / neutralization cycles (5 sec each for three cycles) alternating between 10 mM glycine (pH 2.0) and 1× kinetics buffer, respectively. After regeneration, the biosensors were reused for subsequent binding analyses.
[0145] Human recombinant LIF produced from mammalian cells (LIF-H521b) was from ACROBiosystems; human recombinant OSM produced in mammalian cells (8475-OM / CF) was from R&D; and human recombinant OSM produced in E. coli cells (295-OM-050 / CF) was from R&D.
[0146] Example 18 - Crystal structure of h5D8 fab Five crystal structures of h5D8 Fab have been determined under a wide range of chemical conditions. The high resolution of these structures indicates that the conformations of the CDR residues are highly similar in various chemical environments, associated with low conformational flexibility. A unique feature of this antibody is the presence of a non-canonical cysteine at position 100 in the variable heavy chain region. Structural analysis shows that the cysteine is unpaired and largely solvent inaccessible.
[0147] The h5D8 Fab was obtained by papain digestion of its IgG, followed by purification using standard affinity, ion exchange and size chromatography techniques. Crystals were obtained using vapor diffusion techniques and five crystal structures were determined with resolutions ranging from 1.65 Å to 2.0 Å. All structures resolved into the same crystal space group and had similar unit cell dimensions (P212121, a ~ 53.8 Å, b ~ 66.5 Å, c ~ 143.3 Å) despite crystallization conditions spanning five different pH levels: 5.6, 6.0, 6.5, 7.5 and 8.5. These crystal structures therefore allow the comparison of the three-dimensional configuration of the h5D8 Fab across a wide range of chemical conditions, unhindered by crystal packing artifacts.
[0148] Electron density was observed for all complementarity determining region (CDR) residues, which were subsequently modeled. Remarkably, LCDR1 and HCDR2 adopted an elongated conformation that together with the shallow LCDR3 and HCDR3 regions formed a binding groove at the center of the antigen-binding site (Figure 14A). The five structures are highly similar across all residues, with root mean square deviations of all atoms ranging from 0.197 Å to 0.327 Å (Figure 14A). These results showed that the conformations of the CDR residues were maintained in various chemical environments, including pH levels ranging from 5.6 to 8.5 and ionic strengths ranging from 150 mM to 1 M. Analysis of the electrostatic surface of the h5D8 antigen-binding site revealed that positively and negatively charged regions contributed equally to the hydrophilic character, without a predominant hydrophobic patch. h5D8 has the unusual feature of a non-canonical cysteine at the base of HCDR3 (Cys100). In all five structures, this free cysteine is aligned and does not form a disulfide scramble. Furthermore, the free cysteine is not modified by the addition of Cys (cysteinylation) or glutathione (glutathionylation) and makes van der Waals interactions (3.5-4.3 Å distances) with the side chain atoms of Leu4, Phe27, Trp33, Met34, Glu102 and Leu105 of the main and heavy chains (Figure 14B). Finally, Cys100 is a largely buried structural residue that is likely involved in mediating the conformation of CDR1 and HCDR3. It is therefore unlikely to be reactive with other cysteines, as observed by the homogeneous arrangement of this region in our five crystal structures.
[0149] method h5D8-1 IgG was obtained from Catalent Biologics and prepared in 25 mM histidine, 6% sucrose, 0.01% polysorbate 80, pH 6.0. Prepared IgG was extensively buffer exchanged in PBS using 10K MWCO concentrators (Millipore) prior to digestion with 1:100 μg papain (Sigma) in PBS, 1.25 mM EDTA, 10 mM cysteine for 1 h at 37°C. Papain-digested IgG was run through a Protein A column (GE Healthcare) using an AKTA Start chromatography system (GE Healthcare). Protein A flow-through containing h5D8 Fab was collected and buffer exchanged into 20 mM sodium acetate, pH 5.6, using 10K MWCO concentrators (Millipore). The resulting sample was loaded onto a Mono S cation exchange column (GE Healthcare) using an AKTA Pure chromatography column (GE Healthcare). Elution with a gradient of 1 M potassium chloride yielded the predominant h5D8 Fab peak that was collected, concentrated, and purified to a homogeneous size using a Superdex 200 Increase gel filtration column (GE Healthcare) in 20 mM Tris-HCl, 150 mM sodium chloride, pH 8.0. The high purity of the h5D8 Fab was confirmed by SDS-PAGE under reducing and non-reducing conditions.
[0150] Purified h5D8 Fab was concentrated to 25 mg / mL using a 10K MWCO concentrator (Millipore). Vapor diffusion crystallization experiments were set up using commercial screens JCSG TOP96 (Rigaku Reagents) and MCSG-1 (Anatrace) in dilute matrix 96 conditions at 20 °C using an Oryx 4 dispenser (Douglas Instruments). Crystals were obtained under five crystallization conditions: 1) 0.085 M sodium citrate, 25.5 (w / v)% PEG 4000, 0.17 M ammonium acetate, 15 (v / v)% glycerol, pH 5.6; 2) 0.1 M MES, 20 (w / v)% PEG 6000, 1 M lithium chloride pH 6.0; 3) 0.1 M MES, 20 (w / v)% PEG 4000, 0.6 M sodium chloride, pH 6.5; 4) 0.085 M sodium HEPES, 17 (w / v)% PEG 4000, 8.5 (v / v)% 2-propanol, 15 (v / v)% glycerol, pH 7.5; and 5) 0.08 M Tris, 24 (w / v)% PEG. Crystals were harvested after 4 days in 4000, 0.16 M magnesium chloride, 20 (v / v)% glycerol, pH 8.5. Prior to flash freezing in liquid nitrogen, the mother liquor containing the crystals was supplemented with 5-15 (v / v)% glycerol or 10 (v / v)% ethylene glycol as needed. Crystals were subjected to X-ray synchrotron radiation at the Advanced Photon Source, beamline 23-ID-D (Chicago, IL) and diffraction patterns were recorded on a Pilatus3 6M detector. Data were processed using XDS and structures were determined by molecular replacement using Phaser. Refinement was performed in PHENIX using iterative model building in Coot. Figures were generated in PyMOL. All software was accessed through SBGrid.
[0151] Example 19 - Mutation at Cysteine 100 of h5D8 preserve binding Analysis of h5D8 revealed a free cysteine residue at position 100 (C100) in the variable region of the heavy chain. h5D8 mutants were generated by replacing C100 with each natural amino acid to characterize the binding and affinity to human and mouse LIF. Binding was characterized using ELISA and Octet assays. The results are summarized in Table 9. The ELISA EC50 curves are shown in Figure 15 (Figure 15A, human LIF and Figure 15B, mouse LIF).
[0152] [Table 10]
[0153] method ELISA: Binding of h5D8 C100 variants to human and mouse LIF was determined by ELISA. Recombinant human or mouse LIF protein was coated onto Maxisorp 384-well plates at 1 μg / mL overnight at 4° C. Plates were blocked with 1× blocking buffer for 2 hours at room temperature. Titrations of each h5D8 C100 variant were added and allowed to bind for 1 hour at room temperature. Plates were washed 3 times with PBS+0.05% Tween-20. HRP-conjugated anti-human IgG was added and allowed to bind for 30 minutes at room temperature. Plates were washed 3 times with PBS+0.05% Tween-20 and developed with 1× TMB substrate. Reactions were stopped with 1M HCl and absorbance at 450 nm was measured. Generation of figures and nonlinear regression analysis was performed using Graphpad Prism.
[0154] Octet RED96: The affinity of h5D8 C100 variants for human and mouse LIF was determined by BLI using the Octet RED96 system. h5D8 C100 variants were loaded onto anti-human Fc biosensors at 7.5 μg / mL, followed by a 30 s baseline in 1× kinetics buffer. Titrations of human or mouse LIF protein were associated with the loaded biosensor for 90 s and allowed to dissociate in 1× kinetics buffer for 300 s. KD was calculated by the data analysis software using a 1:1 global fitting model.
[0155] Example 20 - h5D8 blocks LIF binding to gp130 in vitro To determine whether h5D8 prevents LIF from binding to LIFR, a molecular binding assay using the Octet RED 96 platform was performed. h5D8 was loaded onto the AHC biosensor by anti-human Fc capture. The biosensor was then immersed in LIF, and as expected, association was observed (Figure 16A, third in the middle). The biosensor was then immersed in various concentrations of LIFR. A dose-dependent association was observed (Figure 16A, third in the right). Control experiments demonstrated that this association was LIF-specific (not shown) and was not due to non-specific interactions with h5D8 or the biosensor.
[0156] To characterize the binding of h5D8 and LIF in detail, a series of ELISA binding experiments were performed. h5D8 and LIF were preincubated and then introduced to plates coated with either recombinant human LIFR (hLIFR) or gp130. The lack of binding between the h5D8 / LIF complex and the coated substrate indicates that h5D8 somehow disrupted the binding of LIF to the receptor. In addition, control antibodies were also used that either did not bind to LIF (isotype control, indicated with (-)) or bound to LIF at a known binding site (B09 does not compete with either gp130 or LIFR for LIF binding; r5D8 is the rat parent version of h5D8). The ELISA results showed that the h5D8 / LIF complex was able to bind to hLIFR (as was the r5D8 / LIF complex), indicating that these antibodies do not interfere with LIF / LIFR association (Figure 16A). In contrast, the h5D8 / LIF complex (and r5D8 / LIF complex) was unable to bind recombinant human gp130 (Fig. 16B), indicating that the gp130-binding site of LIF was affected when LIF bound to h5D8.
[0157] Example 21 - Expression of LIF and LIFR in human tissues Quantitative real-time PCR was performed in a number of different types of human tissues to determine the expression levels of LIF and LIFR. The average expression levels shown in Figures 17A and 17B are copies per 100 ng of total RNA. The majority of tissues expressed at least 100 copies per 100 ng of total RNA. LIF mRNA expression was highest in human adipose tissue (mesenteric ileum [1]), vascular tissue (choroid plexus [6] and mesentery [8]), and umbilical cord
[68] tissues, and lowest in brain tissue (cortex
[20] and substantia nigra
[28] ). LIFR mRNA expression was highest in human adipose tissue (mesenteric ileum [1]), vascular tissue (lung [9]), brain tissue [11-28], and thyroid
[66] tissues, and lowest in PBMCs
[31] . Expression levels of LIF and LIFR mRNA in cynomolgus monkey tissues were similar to those observed in human tissues, where LIF expression was high in adipose tissue and LIFR expression was high in adipose tissue and low in PBMCs (data not shown).
[0158] The numbering of tissues for Figures 17A and 17B is: 1-Adipose (mesenteric ileum); 2-Adrenal gland; 3-Bladder; 4-Bladder (trigone); 5-Vessel (brain: middle cerebral artery); 6-Vessel (choroid plexus); 7-Vessel (coronary artery); 8-Vessel (mesenteric (colon)); 9-Vessel (lung); 10-Vessel (kidney); 11-Brain (tonsil); 12-Brain (caudate nucleus); 13-Brain (cerebellum); 14-Brain (cortex: anterior cingulate); 15-Brain (cortex: posterior cingulate); 16 -Brain(cortex:frontal-temporal);17-Brain(cortex:frontal-midhead);18-Brain(cortex:occipital);19-Brain(cortex:anterior parietal);20-Brain(cortex:temporal);21-Brain(dorsal raphe nucleus);22-Brain(hippocampus);23-Brain(hypothalamus:anterior);24-Brain(hypothalamus:posterior);25-Brain(locus coeruleus);26-Brain(medulla oblongata);27-Brain(nucleus accumbens);28-Brain(substantia nigra);29-thorax;30-cecum;31-peripheral blood mononuclear cells( PBMC);32-Colon;33-Dorsal root ganglion (DRG);34-Duodenum;35-Fallen tube;36-Gallbladder;37-Heart (left atrium);38-Heart (left ventricle);39-Ileum;40-Jejunum;41-Kidney (cortex);42-Kidney (medulla);43-Kidney (pelvis);44-Liver (parenchyma);45-Liver (Bronchi:main);46-Liver (Bronchi:tertiary);47-Lung (parenchyma);48-Lymph gland (tonsil);49-Muscle (skeletal) ;50-esophagus;51-ovary;52-pancreas;53-pineal gland;54-pituitary gland;55-placenta;56-prostate;57-rectum;58-skin (foreskin);69-spinal cord;60-spleen (parenchyma);61-stomach (antrum);62-stomach (body);63-stomach (fundus);64-stomach (pyloric duct);65-testes;66-thyroid gland;67-trachea;68-umbilical cord;69-ureter;70-uterus (cervix);71-uterus (myometrium);and 72-vas deferens.
[0159] Example 22 - Dose Selection, Dose Escalation and Uniform Administration Dose selection, dose escalation and uniform administration of anti-LIF antibodies are described below. Mice and cynomolgus monkeys were used for the safety evaluation of h5D8.
[0160] No treatment-related adverse effects were observed in 4-week GLP toxicity studies in mice and monkeys receiving weekly IV doses up to 100 mg / kg. Thus, the Highest No Significant Toxicity Dose (HNSTD) was established to be >100 mg / kg and the No Observed Adverse Effect Level (NOAEL) was established to be 100 mg / kg IV in both species under the conditions of this study. Dose was scaled to establish the Human Equivalent Dose (HED). A body surface area (BSA)-based scaling approach was used to estimate the HED. Based on these GLP toxicity studies, the Maximum Recommended Starting Dose (MRSD) was estimated as shown below: 0.81mg / kg IV HED using a 10-fold safety factor from the NOAEL in mice >10mg / kg IV based on the dose causing severe toxicity in 10% of mice 3.2 mg / kg IV HED using a 10-fold safety factor from the cynomolgus monkey NOAEL >16.7mg / kg IV based on 1 / 6 of HNSTD Based on toxicity studies and taking into account a conservative approach for the advanced cancer patient population in Phase 1 trials, a MRSD of 1 mg / kg (or a flat dose of 75 mg) IV was supported by the data.
[0161] The pharmacologically active dose (PAD) was also considered when setting the MRSD. Based on the pharmacology, PK and LIF stabilization data in mouse pharmacology models available to date, the following approach was used to estimate the PAD. Based on the dose response in the U251 mouse xenograft model, the optimally effective dose appeared to be approximately 300 μg IP twice weekly, and this dose level was associated with a pre-last dose trough serum concentration of approximately 230 μg / mL. There was evidence that maximal stabilization of serum LIF levels was achieved at this 300 μg dose in this model, which was further supported by serum LIF stabilization data in mouse GLP toxicity studies at doses of 10, 30 and 100 mg / kg. Using a two-compartment model fitted to the monkey PK data and scaled to humans, a clinical dose of 1500 mg every 3 weeks would result in a C of approximately 500 μg / mL. trough Similarly, the minimally effective dose of 20 μg twice weekly in this U251 mouse xenograft model was associated with a pre-last-dose trough serum concentration of approximately 20 μg / mL; there was evidence that the 20 μg dose only achieved approximately 50% of maximum serum LIF stabilization, which was supported by evidence that a dose of 0.5 mg / kg IV in a mouse PK tolerability study provided minimal LIF stabilization. A clinical dose of 75 mg every 3 weeks provided approximately 25 μg / mL of C trough Additional PK-PD (LIF stabilized) data available from mouse syngeneic models supported the PAD derived from the U251 mouse xenograft model.
[0162] Therefore, a starting dose of 75 mg (iv) was deemed appropriate based on toxicity study data in both mice and monkeys and the minimally effective dose in a mouse xenograft model. A maximum clinical dose of 1500-2000 mg was supported by toxicity study data. A uniform dosing approach was appropriate based on the observation of linear PK in animal models, coupled with the absence of test article-related adverse findings.
[0163] Example 23 - Phase 1 dose escalation and dose escalation study of h5D8 A Phase 1 clinical trial was designed to establish the safety profile and proper dosing of h5D8 in monotherapy against a cross-section of cancer. The primary objectives were: 1) to evaluate the safety and tolerability of h5D8 in patients with advanced solid tumors; 2) to determine the recommended dose for h5D8 monotherapy; and 3) to evaluate the preliminary antitumor activity, as measured by overall response rate (ORR), of h5D8 according to RECIST 1.1 criteria. Secondary objectives were: to characterize the PK and immunogenicity of h5D8; and 2) to evaluate efficacy parameters in patients with advanced solid tumors, including disease control rate (DCR) and progression-free survival (PFS) according to RECIST 1.1. Exploratory objectives were to: 1) explore the relationship between pharmacokinetics, pharmacodynamics, and h5D8 exposure to patient safety and antitumor activity; b) evaluate whether antitumor LIF expression correlates with the antitumor activity of h5D8; c) characterize the pharmacodynamic effects of h5D8 in the periphery and tumor, and d) characterize the impact of h5D8 treatment on exploratory biomarkers.
[0164] The study was designed as an open-label Phase 1 trial, enrolling patients with advanced solid tumors. The study was conducted and is ongoing (75 mg, 225 mg, 750 mg, 1125 mg, and 1500 mg dose cohorts) in an accelerated titration 3+3 design with a uniform dose of h5D8 administered intravenously once Q3W.
[0165] Antitumor response studies were designed to be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in Oncology Clinical Trials. Assessments were designed to occur at baseline and every 6 weeks for the first 6 months and then every 12 weeks thereafter until documented disease progression or patient withdrawal. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, and were designed to be continuously assessed during the study and for 30 days after the last treatment. Forty-one patients were enrolled and administered the treatment. Patient demographics are shown in Table 10.
[0166] [Table 11]
[0167] Dose-limiting toxicities (DLTs) were defined as follows: 1) observed on day 1 of the 21 days following cycle 1, assessed with the consent of the investigator in agreement with the data review committee (DRC) as potentially related to h5D8; 2) any drug-related grade ≥3 adverse event (AE). AEs with clear alternative explanations and pre-specified, self-limited grade 3 AEs were considered to be non-DLTs, including: 1) fatigue, nausea, vomiting, or diarrhea that remitted to grade ≤2 within 72 hours with appropriate medical therapy; 2) transient (duration ≤72 hours) grade 3 biochemical abnormalities that were not considered clinically significant; 3) grade 3 neutropenia lasting ≤72 hours; and 4) grade 3 thrombocytopenia without clinically significant bleeding. Any grade drug-related AE that delays the start of cycle 2 day 1 for more than 14 days may be considered a DLT by the DRC. A safety study summary to date for cohorts 1-5 is shown in Table 11.
[0168] [Table 12]
[0169] No dose-limiting toxicity or tolerability issues were observed at any dose. Overall, these data indicate that h58 was safe and well tolerated at all doses tested.
[0170] Example 24 - Case Study of a Patient Treated with h5D8 Subject 0106-002 is a 68 year old Caucasian female with stage IV pancreatic cancer who had been pretreated multiple times with 4 lines of prior systemic anti-cancer therapy for metastatic disease. The subject was initially diagnosed with stage II / III moderately to poorly differentiated pancreatic ductal adenocarcinoma. The subject was treated with neoadjuvant FLOFIRINOX for approximately 167 days and achieved a partial response. The subject underwent a "curative" laparoscopic distal pancreatectomy and pancreaticosplenectomy followed by approximately 7 months of adjuvant gemcitabine at which time the subject developed recurrent "progression" in the pancreatic bed. The subject was treated with gemcitabine and Abraxane for approximately 2 months with the best outcome being a partial response, followed by "progression" in the pancreatic bed and celiac lymph nodes. The subject then received 5FU and Onivyde (liposomal irinotecan) for approximately 2 weeks, which was discontinued due to toxicity. For approximately 2 months, the subject was treated with an investigational Wnt inhibitor (Samumed) but had "progression" with malignant lymphadenopathy above and below the diaphragm. For approximately 4 months, the subject received a pyrimidine nucleoside metabolic inhibitor (Fujiflim) with the best response being a "partial response." The subject was enrolled in the h5D8 clinical trial as radiographic progression and increasing CA19-9 were documented. The results of the treatments she received prior to the h5D8 clinical trial are summarized in Table 13. (PR=partial response; PD=progression; SD=stable disease)
[0171] [Table 13]
[0172] The subject received her first dose of h5D8 at 1125 mg, with her most recent dose being Cycle 9 (C9) (1500 mg) approximately 165 days later. At baseline, the subject had no clinically significant laboratory abnormalities; Eastern Cooperative Oncology Group ("ECOG") status = 1; elevated CA19-9 of 1658. Two lymph nodes (one chest and one abdominal) were identified as target lesions, while abdominal lymphadenopathy was identified as a non-target lesion. On Cycle 3 Day 1 ("C3D1"), her ECOG status improved to 0, CA19-9 decreased to 1069, and the overall RECIST response was "stable." Historically, CA19-9 has been a reliable predictive marker of disease. According to the physician, oxycodone use, which was required for abdominal pain, was no longer necessary. The subject took Cycle 6 and approximately two weeks later, the patient's analgesic requirements increased and she was hospitalized at a location remote from the trial site. The subject is now back to baseline requiring narcotic analgesics twice daily. The subject had a repeat scan which showed "stable". Her CA19-9 increased at the time of Cycle 5 but returned to below baseline and below the initial decline at Cycle 3 by Cycle 9. The results are shown in Table 13. The subject did not experience any adverse events from treatment.
[0173] [Table 14]
[0174] Subject 0102-001 is a 78-year-old Caucasian female with stage IV uterine leiomyosarcoma who had been pretreated multiple times with 6 lines of systemic anticancer therapy. The subject was initially diagnosed with T1B uterine leiomyosarcoma and had a local recurrence approximately 3 years after the initial diagnosis with curative TAH / BSO, which was treated with surgical resection; chemoradiation was declined. The subject recurred approximately 2 years later and was treated with 4 cycles of gemcitabine and docetaxel with mixed response. The subject then received 3 cycles of doxil with the best response achieved being "progression." This was followed by 2 months of vinorelbine with the best response achieved being PD. Trabectidin was administered for approximately 4 months with mixed response and was discontinued due to toxicity. The subject was then treated with DTIC for 4 months with the best response achieved being PD. The subject received radiation therapy (XRT) to the primary intramedullary mass for a total of 3750 cGy in 10 fractions over approximately 22 days, followed by Votrient for approximately 1 month, with the best response being PD. The results of her previous treatments are shown in Table 14.
[0175] [Table 15]
[0176] At baseline, the subject had no clinically significant laboratory values; ECOG=1, and an elevated CA-125 of 13. The subject received an initial dose of h5D8 at 750 mg and her CA-125 had decreased to 9 with C3. At the time of evaluation for C5, her CA-125 was 8 and the overall RECIST response was "stable."
[0177] From her baseline scan, one lung lesion, one liver lesion, two rectus muscle lesions, and one pelvic blind pouch lesion were identified as target lesions, and the abdominal lesion was identified as a non-target lesion. At the time of C7 evaluation, her CA-125 was 9 and the subject had an overall RECIST response of "stable". C7 images of the three target lesions and previous radiation therapy ports are shown in Figures 18A-C. The above results are shown in Table 15.
[0178] [Table 16]
[0179] Subject 0101-001 is a 50 year old Caucasian female with stage IV KRAS+ colorectal cancer who had received first line systemic anti-cancer therapy for metastatic disease. The subject was initially diagnosed with stage III moderately differentiated colorectal adenocarcinoma (T3N2M0). The subject underwent curative robotic low anterior resection followed by adjuvant 5FU and FOLFOX for approximately 7 months. The subject recurred with pulmonary metastases approximately 2 years later and elected to expectant management and did not receive palliative systemic therapy for her stage IV disease. Approximately 1 year after recurrence, the pulmonary metastases continued to progress. The subject refused first line chemotherapy for mCRC and chose the h5D8 clinical trial as her first line therapy.
[0180] The subject received her first dose of h5D8 at 225 mg and her most recent dose was C6 (750 mg) approximately 4 months later. At baseline, the subject had no clinically significant laboratory abnormalities; ECOG status = 0; elevated tumor marker (CEA) of 11.8. Two right lower lobe lesions were identified as target lesions and two non-target lesions (ovary and bone) were identified. At C3 assessment, the response was "stable" and CEA had elevated to 11.8. At C5 assessment, the subject had "stable" disease but continued to progress radiologically after C6 treatment. Results are shown in Table 16.
[0181] [Table 17]
[0182] Subject 0106-005 is a 75 year old Caucasian female with fallopian tube cancer. Subject underwent curative TAH BSO, LNectomy and debulking followed by adjuvant carboplatin and taxol. Subject recurred with malignant adenopathy approximately 5 years later and received palliative radiation therapy (55 cGy) to LNs at the aortic bifurcation. Subject had LN progression and received palliative radiation therapy (60 cGy) to periaortic LNs. Subject developed pulmonary metastases and was treated with an investigational BET inhibitor for approximately 1 month, which was discontinued due to toxicity, followed by an investigational anti-PD-1 for approximately 4 months with a best response of "stable disease." Subject was then treated with an investigational TIGIT inhibitor for approximately 200 days with a best response of "stable disease." After progression, the subject was treated with an investigational monoclonal antibody for approximately 4 months with a best response of "stable disease." The subject had documented progression and was enrolled in the h5D8 clinical trial. The results of her prior treatments are shown in Table 17.
[0183] [Table 18]
[0184] The subject received an initial dose of 750 mg of h5D8; after 2 months on C4, the dose of the h5D8 cycle was increased to 1125 mg. Her final dose (C6) was administered approximately 44 days after this dose escalation. The subject had radiological progression approximately 1 month after treatment and performed her EOT (end of study drug) visit. At baseline, the subject had no clinically significant laboratory values and ECOG performance status = 1. The subject did not develop tumor markers in the blood. Two lung lesions (one in the right upper lobe and one in the left thoracic inlet) were selected as target lesions, and multiple lung nodules were selected as non-target lesions. The subject experienced no treatment-related adverse events. The results of these trials are shown in Table 18.
[0185] [Table 19]
[0186] Subject 0301-002 is a 66 year old Caucasian female diagnosed with ovarian cancer. The subject was treated with neoadjuvant carboplatin and taxol followed by a curative hysterectomy, BSO and omentectomy approximately 4 months later, followed by approximately 3 months of additional carboplatin / taxol. The subject relapsed approximately 8 months later and received palliative chemotherapy with carboplatin / taxol for approximately 6 months; no best response was reported. The subject showed radiological progression approximately 3 months after this chemotherapy and was treated with doxorubicin for approximately 7 months with a best response of "stable disease"; the subject progressed again approximately 4 months later. The subject then received single agent taxol for approximately 3 months with a best response of "progression." For approximately 6 months the subject was treated with gemcitabine and carboplatin with a best response of "stable disease." The subject had radiological progression approximately 3 months after this treatment and was enrolled in the h5D8 clinical trial. The results from her prior treatment are shown in Table 19.
[0187] [Table 20]
[0188] The subject received an initial dose of 1500 mg of h5D8. Her most recent dose, C7, was approximately 5 months later. At baseline, the subject had no clinically significant laboratory values and an ECOG performance status = 0. Her CA-125 was 412.3 at baseline. Three lesions were selected as target lesions (one pancreatic implant, one soft tissue in the subcostal area, and one pleural nodule) and three non-target lesions were identified (liver, peritoneal, and retroperitoneal nodule). The subject experienced no treatment-related adverse events. The results of her trial are shown in Table 20.
[0189] [Table 21]
[0190] Subject 0102-004 is a 65 year old Caucasian female diagnosed with head and neck cancer. The subject underwent curative total glossectomy and received adjuvant radiation therapy (6000cGy) one month later. The subject recurred with pulmonary metastases approximately 10 months later and was subsequently irradiated (5000cGy) for approximately one week. There was progression of pulmonary disease and new bone metastases 8 months after radiation and the subject was treated with ipilimumab and nivolumab for approximately one year and 45 days with a best response of "stable disease". The subject had radiological progression and was enrolled in the h5D8 clinical trial. The results of her prior treatments are shown in Table 21.
[0191] [Table 22]
[0192] The subject received her first dose of h5D8 at 1500 mg, with her most recent dose being C7 approximately 155 days later. At baseline, the subject had no clinically significant laboratory values and an ECOG performance status = 1. The subject did not express peripheral blood tumor markers. Four lesions (two lung lesions and two pleural lesions) were selected as target lesions, and two bone lesions were identified as non-target lesions. The results are shown in Table 22.
[0193] [Table 23]
[0194] Subject 0201-003 is a 57 year old Caucasian male diagnosed with myxoid liposarcoma. The subject was treated with neoadjuvant adriamycin and ifosfamide for approximately 4 months and neoadjuvant radiation therapy (5000 cGy) to the right calf for approximately 35 days. The subject then underwent curative wide resection of the right calf, resection of the posterior tibial nerve, and removal of the popliteal, anterior and posterior tibial and peroneal vessels. The subject had recurrent pleural disease and malignant lymphadenopathy in the chest. The subject was treated with gemcitabine and taxotere for approximately 41 days with a best response of "progression." The subject was then treated with dacarbazine for 4 months with a best response of "partial response." The subject had radiological progression after 22 days and was enrolled in the h5D8 clinical trial. The results of her previous treatments are shown in Table 23.
[0195] [Table 24]
[0196] The subject received her first dose of h5D8 at 1125 mg, with her most recent dose being (C6) (1500 mg) approximately 136 days later. At baseline, the subject had no clinically significant laboratory abnormalities and an ECOG performance status = 1. The subject had no peripheral blood tumor markers. Two pleural masses were selected as target lesions and three non-target lesions (one pleural mass and two LNS) were selected. The results are shown in Table 24. The subject did not experience any treatment-related adverse events.
[0197] [Table 25]
[0198] Example 25 - Biomarkers indicating a positive response to h5D8 treatment Subject 0201-003 is a 57 year old Caucasian male diagnosed with myeloid liposarcoma. The results of his current treatment are shown in Table 23. The subject's h5D8C5 evaluation after 12 weeks showed no increase by RECIST criteria in his bulky pulmonary metastatic target lesions (167mm). See Table 24. The subject is on treatment regimen (+14 weeks) with best response recorded as "stable." A biopsy sample from the metastatic lung site was collected to determine biomarkers of h5D8 treatment. At the time the biopsy was taken, the subject showed evidence of saturating LIF stabilization. The LIF stabilization of subject 0201-003 is shown in Figure 19.
[0199] Biomarkers for anti-tumor immunity were observed in "on-treatment" biopsies compared to pre-h5D8 treatment. Results are shown in Figures 20A-C. Results show an increase in CD8 positive T cell infiltration, as well as an increase in the tumor-associated macrophage ("TAM") population. See Figure 20A. TAMs exhibited an immunostimulatory phenotype (MHCII+). See Figure 20B. A decrease in pSTAT3+ nuclei was also observed. See Figure 20C.
[0200] Subject 0301-003 is a 47 year old Caucasian female with stage IV retroperitoneal paraganglioma. Her pre-h5D8 treatment results are shown in Table 25.
[0201] [Table 26]
[0202] Her h5D8 C3 evaluation after 6 weeks showed stable CEA levels (0.5ng / ml) and "stable" by RECIST criteria for lung and liver metastatic target lesions. The subject remained on the treatment regimen (+11 weeks) with best response recorded as "stable." Biopsy samples from metastatic liver sites were collected to determine biomarkers of h5D8 treatment. LIF stabilization data was not processed at this time point.
[0203] Biomarkers for anti-tumor immunity were observed in "on-treatment" biopsies compared to pre-h5D8 treatment. Results are shown in Figures 21A-C. These results showed an increase in CD8 positive T cell infiltration. See Figure 21A and reduced TAM polarization towards an inhibitory phenotype (CD163+;CD206+). See Figure 21B. A decrease in pSTAT+ nuclei was also observed. See Figure 21C.
[0204] Subject 0301-004 is a 74 year old Caucasian male with stage IV pancreatic adenocarcinoma. The subject had received two lines of therapy prior to h5D8 treatment. The results of his prior therapy are shown in Table 26.
[0205] [Table 27]
[0206] Subject 0301-004 had a highly aggressive cancer that essentially rapidly failed two first line treatment regimens administered at the time of tumor onset, including immediate "progression" status on FOLFOX. Subject received h5D8 treatment regimen (6 weeks). Biopsy samples were collected from metastatic liver sites. LIF stabilization data was not processed at this time point.
[0207] Biomarkers for anti-tumor immunity were observed in "on-treatment" biopsies compared to pre-h5D8 treatment. Results are shown in Figure 22. Immunohistochemistry showed that LIF low This resulted in subjects characterized as having high CD8+ T cell populations in the tumor microenvironment despite undergoing highly aggressive chemotherapy regimens and rapid disease progression. See Figure 22. A modest effect on macrophage populations was observed (data not shown). Furthermore, no difference was observed in pSTAT3+ nuclei (data not shown).
[0208] Subject 0201-004 is a 66 year old Caucasian male with stage IV melanoma. Subject had received one treatment prior to the h5D8 clinical trial. Best response was not assessable and results are not shown (nivolumab; 4 months). Failed nivolumab treatment demonstrated severe tumor immunosuppression. Subject received treatment regimen (6 weeks) with best response recorded as "progression." Biopsy specimens were collected from metastatic skin sites. At the time of biopsy collection, subjects generally had high levels of LIF observed by stabilization assay with no evidence of saturation of LIF stabilization. Results of LIF stabilization assay are shown in Table 23.
[0209] Biomarkers for anti-tumor immunity were observed in "on-treatment" biopsies compared to pre-h5D8 treatment. Results are shown in Figure 24. Immunohistochemistry showed that LIF high This resulted in subjects characterized as having STAT3+ T-cell proliferation and proliferation in the tumor. Macrophage analysis was restricted to the tumor microenvironment (TME) and showed little change in T cell activity (data not shown). Increased macrophage phenotype polarization was observed for MHCII+. See FIG. 24. Preliminary results of manual pathology show that pSTAT3+ nuclei are decreased in treatment samples.
[0210] Subject 0301-002 is a 66 year old Caucasian female diagnosed with ovarian cancer. The results of her current treatment are shown in Table 19. The subject's h5D8 C5 evaluation after 12 weeks showed an increase in CA19-9 (412-1072U / ml), but her target lesions showed no significant increase by RECIST criteria (107-109mm). See Table 20. The subject is undergoing treatment regimen (+16 weeks) with best response recorded as "stable." Biopsy samples from metastatic lymph node sites were collected to determine biomarkers of h5D8 treatment. At the time the biopsy was taken, the subject showed evidence of saturating LIF stabilization. Subject 0201-003's LIF stabilization is shown in Figure 25.
[0211] Biomarkers for anti-tumor immunity were observed in "on-treatment" biopsies compared to pre-h5D8 treatment. There were no observable changes in tumor immune biomarkers (data not shown). Immunohistochemistry demonstrated that LIF low This gave rise to an object that can be characterized as:
[0212] A summary of the results of the above assays to determine biomarkers for effective h5D8 treatment is shown in Table 27. Multiple parameters demonstrate the effect of h5D8 treatment on increased anti-tumor immunity, TAM regulation and LIF signaling (NC=no change; NE=no effect).
[0213] [Table 28]
[0214] Example 26 - PK / PD of h5D8 in subjects receiving hD5 To determine the pharmacokinetics of h5D8 antibody in humans, levels of h5D8 were measured in the serum of treated patients from clinical trials. Briefly, quantification of h5D8 antibody in human serum samples was performed by sandwich immunoassay. h5D8 antibody in patient serum samples was captured on rhuLIF (recombinant human LIF) coated MSD plates and detected by sulfo-labeled anti-human IgG (sulfo anti-h5d8-Fab2-IgG) antibody. The sulfo signal was measured by MSD Reader S600 and quantified using an h5D8 standard curve. Results shown in Figure 26 revealed that h5D8 exhibited standard pharmacokinetics with an estimated half-life of approximately 17 days. Furthermore, these results indicate that h5D8 exhibits linear PK over a dose range of 750-1500 mg every 3 weeks, with saturation of target-mediated pharmacokinetics occurring above 225 mg.
[0215] To determine whether targeting LIF is engaged by the h5D8 antibody, a capture ELISA assay was used to determine total LIF levels after treatment. LIF has a relatively short half-life in plasma and increases upon binding by h5D8, resulting in increased plasma LIF levels. Thus, increased LIF levels in peripheral blood indicate target engagement. Figures 27A-B show the time course of total LIF levels in multiple patients after receiving an intravenous dose of h5D8. Taken together, the data indicate target saturation after three cycles of drug administration at non-saturating dose levels (cohorts 2-3). See Figure 27B.
[0216] Total LIF levels in patient serum samples were quantified by sandwich immunoassay. Briefly, MSD plates were spot-coated with anti-LIF A4 capture antibody (rabbit monoclonal). After incubation with patient serum samples, bound LIF / h5D8 complexes were detected by sulfo-tagged anti-LIF antibody 7C3 PB001. Sulfo signals were measured by MSD Reader S600, and patient serum LIF / h5D8 levels were quantified using a rhLIF / h5D8 standard curve.
[0217] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous modifications, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various modifications of the embodiments of the invention described herein can be used in practicing the invention.
[0218] All publications, patent applications, issued patents, and other documents mentioned herein are incorporated by reference herein to the same extent as if each individual publication, patent application, issued patent, or other document was specifically and individually indicated to be incorporated by reference in its entirety. Definitions contained in the text incorporated by reference are excluded to the extent they conflict with definitions in this disclosure.
[0219] Sequence Listing [Table 29]
[0220] [Table 30]
[0221] [Table 31]
Claims
1. 1. A method of treating an individual having cancer, comprising administering to said individual: a) an immunoglobulin heavy chain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 1-3; b) an immunoglobulin heavy chain complementarity determining region 2 (VH-CDR2) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 4 or 5; c) an immunoglobulin heavy chain complementarity determining region 3 (VH-CDR3) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 6-8; d) an immunoglobulin light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 9 or 10; e) an immunoglobulin light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence set forth in any one of SEQ ID NOs: 11 or 12; and f) administering a recombinant antibody that specifically binds to leukemia inhibitory factor (LIF), the antibody comprising an immunoglobulin light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence set forth in SEQ ID NO: 13; wherein said recombinant antibody is administered to said individual in a dose of about 75 to about 2000 mg.
2. The method of claim 1 , wherein the recombinant antibody binds to glycosylated LIF.
3. The method of claim 1 or 2, wherein the recombinant antibody is humanized.
4. The method of any one of claims 1 to 3, wherein the recombinant antibody is deimmunized.
5. The method according to any one of claims 1 to 4, wherein the recombinant antibody comprises two heavy immunoglobulin chains and two light immunoglobulin chains.
6. The method of claim 5 , wherein the recombinant antibody is an IgG antibody.
7. The recombinant antibody may be Fab, F(ab) 2 5. The method according to claim 1 , wherein the antibody is a single domain antibody, a single chain variable fragment (scFv) or a nanobody.
8. The recombinant antibody has a dissociation constant (K D The method according to any one of claims 1 to 7, wherein the antibody specifically binds to LIF at the .
9. The recombinant antibody has a dissociation constant (K D The method according to any one of claims 1 to 7, wherein the antibody specifically binds to LIF at the .
10. 10. The method of claim 1, wherein the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 1 (GFTFSHAWMH), the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 4 (QIKAKSDDYATYYAESVKG), the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 6 (TCWEWDLDF), the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 9 (RSSQSLLDSDGHTYLN), the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 11 (SVSNLES), and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13 (MQATHAPPYT).
11. 10. The method of claim 1, wherein the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 2 (GFTFSHAW), the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 5 (IKAKSDDYAT), the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 6 (TCWEWDLDF), the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 10 (QSLLDSDGHTYLN), the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 12 (SVS), and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13 (MQATHAPPYT).
12. 10. The method of claim 1, wherein the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 3 (HAWMH), the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 4 (QIKAKSDDYATYYAESVKG), the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 7 (WEWDLDF), the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO: 9 (RSSQSLLDSDGHTYLN), the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO: 11 (SVSNLES), and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO: 13 (MQATHAPPYT).
13. 13. The method of any one of claims 1 to 12, wherein the cancer comprises advanced solid tumors, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, renal cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma or soft tissue cancer.
14. 14. The method of claim 13, wherein the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma.
15. The method of any one of claims 1 to 14, wherein the recombinant antibody is administered as a component of a pharmaceutical formulation, the pharmaceutical formulation comprising the recombinant antibody and a pharma- ceutically acceptable excipient, carrier or diluent.
16. 16. The method of claim 15, wherein the pharmaceutical formulation has a pH of about 6.
0.
17. 16. The method of claim 15, wherein the pharmaceutical formulation comprises about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80, and wherein the recombinant antibody is present at a concentration of about 20 mg / mL.
18. The method of any one of claims 1 to 17, wherein the recombinant antibody is administered intravenously.
19. The method of any one of claims 1 to 18, wherein the recombinant antibody is administered about once a week.
20. The method of any one of claims 1 to 18, wherein the recombinant antibody is administered about once every two weeks.
21. The method of any one of claims 1 to 18, wherein the recombinant antibody is administered about once every three weeks.
22. The method of any one of claims 1 to 21, wherein the recombinant antibody is administered in a dose of about 750 mg.
23. The method of any one of claims 1 to 21, wherein the recombinant antibody is administered in a dose of about 1125 mg.
24. The method of any one of claims 1 to 21, wherein the recombinant antibody is administered at a dose of about 1500 mg.
25. The method of any one of claims 1 to 21, wherein the recombinant antibody is administered at a dose of about 2000 mg.
26. 1. A method of treating an individual having cancer, comprising administering to said individual: a) an immunoglobulin heavy chain variable region (VH) sequence comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 41, 42, 44, or 66; and b) administering a recombinant antibody that specifically binds to leukemia inhibitory factor (LIF) comprising an immunoglobulin light chain variable region (VL) sequence comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 45-48; wherein said recombinant antibody is administered to said individual in a dose of about 75 to about 2000 mg.
27. 27. The method of claim 26, wherein the VH sequence is at least about 90% identical to the amino acid sequence set forth in SEQ ID NO:42; and the VL sequence is at least about 90% identical to the amino acid sequence set forth in SEQ ID NO:
46.
28. 27. The method of claim 26, wherein the VH sequence is identical to the amino acid sequence set forth in SEQ ID NO: 42; and the VL sequence is identical to the amino acid sequence set forth in SEQ ID NO:
46.
29. The method according to any one of claims 26 to 28, wherein the recombinant antibody comprises two heavy immunoglobulin chains and two light immunoglobulin chains.
30. 30. The method of claim 29, wherein the recombinant antibody is an IgG antibody.
31. 31. The method of any one of claims 26 to 30, wherein the cancer comprises advanced solid tumors, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, renal cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma or soft tissue cancer.
32. 32. The method of claim 31, wherein the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma.
33. 33. The method of any one of claims 26 to 32, wherein the recombinant antibody is administered as a component of a pharmaceutical formulation, the pharmaceutical formulation comprising the recombinant antibody and further comprising a pharma- ceutically acceptable excipient, carrier or diluent.
34. 34. The method of claim 33, wherein the pharmaceutical formulation has a pH of about 6.
0.
35. 34. The method of claim 33, wherein the pharmaceutical formulation comprises about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80, and wherein the recombinant antibody is present at a concentration of about 20 mg / mL.
36. The method of any one of claims 26 to 35, wherein the recombinant antibody is administered intravenously.
37. The method of any one of claims 26 to 36, wherein the recombinant antibody is administered about once a week.
38. The method of any one of claims 26 to 36, wherein the recombinant antibody is administered about once every two weeks.
39. The method of any one of claims 26 to 36, wherein the recombinant antibody is administered about once every three weeks.
40. The method of any one of claims 26 to 39, wherein the recombinant antibody is administered in a dose of about 750 mg.
41. The method of any one of claims 26 to 39, wherein the recombinant antibody is administered in a dose of about 1125 mg.
42. The method of any one of claims 26 to 39, wherein the recombinant antibody is administered at a dose of about 1500 mg.
43. The method of any one of claims 26 to 39, wherein the recombinant antibody is administered at a dose of about 2000 mg.
44. 1. A method of treating an individual having cancer, comprising administering to said individual: a) an immunoglobulin heavy chain sequence comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 57-60 or 67; and b) administering a recombinant antibody that specifically binds to leukemia inhibitory factor (LIF) comprising an immunoglobulin light chain sequence comprising an amino acid sequence that is at least about 90% identical to the amino acid sequence set forth in any one of SEQ ID NOs: 61-64; wherein said recombinant antibody is administered to said individual in a dose of about 75 to about 2000 mg.
45. 45. The method of claim 44, wherein the immunoglobulin heavy chain sequence is at least about 90% identical to the amino acid sequence set forth in SEQ ID NO:58; and the immunoglobulin light chain sequence is at least about 90% identical to the amino acid sequence set forth in SEQ ID NO:
62.
46. 45. The method of claim 44, wherein the immunoglobulin heavy chain sequence is identical to the amino acid sequence set forth in SEQ ID NO:58; and the immunoglobulin light chain sequence is identical to the amino acid sequence set forth in SEQ ID NO:
62.
47. The method according to any one of claims 44 to 46, wherein the recombinant antibody comprises two heavy immunoglobulin chains and two light immunoglobulin chains.
48. 48. The method of any one of claims 44 to 47, wherein the cancer comprises advanced solid tumors, glioblastoma, gastric cancer, skin cancer, prostate cancer, pancreatic cancer, breast cancer, testicular cancer, thyroid cancer, head and neck cancer, liver cancer, renal cancer, esophageal cancer, ovarian cancer, colon cancer, lung cancer, lymphoma or soft tissue cancer.
49. 49. The method of claim 48, wherein the cancer comprises non-small cell lung cancer, epithelial ovarian cancer, or pancreatic adenocarcinoma.
50. 50. The method of any one of claims 44 to 49, wherein the recombinant antibody is administered as a component of a pharmaceutical formulation, the pharmaceutical formulation comprising the recombinant antibody and a pharma- ceutically acceptable excipient, carrier or diluent.
51. 51. The method of claim 50, wherein the pharmaceutical formulation has a pH of about 6.
0.
52. 51. The method of claim 50, wherein the pharmaceutical formulation comprises about 25 mM histidine, about 6% sucrose, and about 0.01% polysorbate 80, and wherein the recombinant antibody is present at a concentration of about 20 mg / mL.
53. The method of any one of claims 44 to 52, wherein the recombinant antibody is administered intravenously.
54. The method of any one of claims 44 to 53, wherein the recombinant antibody is administered about once a week.
55. 54. The method of any one of claims 44 to 53, wherein the recombinant antibody is administered about once every two weeks.
56. 54. The method of any one of claims 44 to 53, wherein the recombinant antibody is administered about once every three weeks.
57. The method of any one of claims 44 to 56, wherein the recombinant antibody is administered at a dose of about 750 mg.
58. The method of any one of claims 44 to 56, wherein the recombinant antibody is administered in a dose of about 1125 mg.
59. The method of any one of claims 44 to 56, wherein the recombinant antibody is administered at a dose of about 1500 mg.
60. The method of any one of claims 44 to 56, wherein the recombinant antibody is administered at a dose of about 2000 mg.
